Document:

Xyrem License and Distribution Agreement dated as of October 29

 Exhibit 4.25 
  

	 CONFIDENTIAL 
	 EXECUTION VERSION 

  

	*	CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN * .

  
 ORPHAN MEDICAL INC. 
  
 AND 
  
 CELLTECH PHARMACEUTICALS LTD. 
  

XYREM® LICENSE AND DISTRIBUTION AGREEMENT 

 TABLE OF CONTENTS 
  

					
	 	 	 	  	Page

	 ARTICLE I
	 	 DEFINITIONS
	  	1
			
	 ARTICLE II
	 	 APPOINTMENT
	  	6
			
	 2.1
	 	Appointment as Distributor	  	6
	 2.2
	 	License Grant	  	7
	 2.3
	 	Right of First Negotiation for Other Indications	  	7
	 2.4
	 	Subdistributors/Sublicensees	  	8
	 2.5
	 	Sales Outside the Territory	  	8
	 2.6
	 	Option to Expand the Territory	  	9
	 2.7
	 	Competitive Product	  	9
			
	 ARTICLE III
	 	 REGULATORY APPROVALS; COMPLIANCE WITH LAWS AND REGULATIONS
	  	9
			
	 3.1
	 	Marketing Authorizations	  	9
	 3.2
	 	Regulatory Timelines	  	10
	 3.3
	 	Other Approvals	  	11
	 3.4
	 	Return of Initial Payment	  	11
	 3.5
	 	Product Changes	  	11
	 3.6
	 	Clinical Trials	  	12
	 3.7
	 	Compliance With Applicable Laws	  	12
	 3.8
	 	Approved Product Packaging and Labeling; Relevant Testing	  	12
	 3.9
	 	Steering Committee	  	13
			
	 ARTICLE IV
	 	 ROYALTIES AND MILESTONE PAYMENTS
	  	14
			
	 4.1
	 	Milestone Payments	  	14
	 4.2
	 	Royalty	  	14
	 4.3
	 	Minimum Royalty Requirement	  	15
	 4.4
	 	Royalty and Milestone Payments	  	15
	 4.5
	 	Exchange Rates	  	16
	 4.6
	 	Taxes	  	16
	 4.7
	 	Reports	  	16
	 4.8
	 	Books and Records; Audit	  	16
			
	 ARTICLE V
	 	 REGULATORY COMPLIANCE; PRODUCT MANUFACTURE
	  	17
			
	 5.1
	 	Regulatory Reporting	  	17
	 5.2
	 	Product Recalls	  	17
	 5.3
	 	Adverse Event Notifications and Reporting	  	17
	 5.4
	 	Correspondence/Complaints	  	17
	 5.5
	 	Translations	  	18
	 5.6
	 	Manufacture; Quality	  	18
	 5.7
	 	Product Specifications	  	18
	 5.8
	 	Manufacturing Audits by Celltech	  	18

  

 i 

 TABLE OF CONTENTS 
  

					
	 	 	 	  	Page

	ARTICLE VI	 	 MARKETING EFFORTS
	  	19
			
	 6.1
	 	Marketing Efforts	  	19
	 6.2
	 	Approved Product Claims	  	19
	 6.3
	 	Development of Marketing Strategy	  	19
	 6.4
	 	Marketing Materials	  	20
	 6.5
	 	Sales and Technical Literature Developed by Orphan Medical	  	20
	 6.6
	 	Marketing Reports	  	20
	 6.7
	 	Cooperation	  	20
	 6.8
	 	Named Patient Basis Sales	  	21
			
	ARTICLE VII	 	 PURCHASE AND DELIVERY OF PRODUCT
	  	21
			
	 7.1
	 	Forecasts	  	21
	 7.2
	 	Pricing	  	22
	 7.3
	 	Consignment of Product	  	22
	 7.4
	 	Purchase Orders.	  	24
	 7.5
	 	Delivery From Other Than Consignment Inventory	  	25
	 7.6
	 	Transfer Price Variations	  	25
	 7.7
	 	Payment Terms	  	26
	 7.8
	 	Short Supply Allocation	  	27
	 7.9
	 	Product Expiration	  	27
	 7.10
	 	Certificate of Analysis	  	28
	 7.11
	 	Storage	  	28
	 7.12
	 	Rejection of Shipments For Product Non-Conformance	  	28
	 7.13
	 	Testing of Product Upon Receipt	  	29
			
	ARTICLE VIII	 	 REPRESENTATIONS AND WARRANTIES
	  	29
			
	 8.1
	 	Orphan Medical Warranties	  	29
	 8.2
	 	Disclaimer	  	32
	 8.3
	 	Celltech Warranties	  	32
			
	ARTICLE IX	 	 INDEMNIFICATION
	  	33
			
	 9.1
	 	Indemnification by Orphan Medical	  	33
	 9.2
	 	Indemnification by Celltech	  	34
	 9.3
	 	Procedure	  	34
	 9.4
	 	Insurance	  	34
			
	ARTICLE X	 	 INTELLECTUAL PROPERTY RIGHTS PERFECTION AND USE
	  	35
			
	 10.1
	 	License Perfection	  	35
	 10.2
	 	Quality Standards	  	35
	 10.3
	 	Use of Trademark	  	35
	 10.4
	 	Registration and Approvals	  	35
	 10.5
	 	Reservation of Rights	  	36

  

 ii 

 TABLE OF CONTENTS 
  

					
	 	 	 	  	Page

	ARTICLE XI	 	 INTELLECTUAL PROPERTY INFRINGEMENTS
	  	36
			
	 11.1
	 	Protection of Intellectual Property	  	36
			
	ARTICLE XII	 	 IMPROVEMENTS
	  	37
			
	 12.1
	 	Improvements by Celltech	  	37
	 12.2
	 	Improvements by Orphan Medical	  	37
	 12.3
	 	Disclosure	  	37
			
	ARTICLE XIII	 	 CONFIDENTIALITY
	  	37
			
	 13.1
	 	Proprietary Information	  	37
	 13.2
	 	Exclusions	  	38
	 13.3
	 	Third Party Disclosure	  	38
	 13.4
	 	Third Party Confidentiality Agreement	  	38
	 13.5
	 	Confidentiality of Agreement	  	39
	 13.6
	 	Prior Confidentiality Agreement	  	39
			
	ARTICLE XIV	 	 TERM AND TERMINATION
	  	39
			
	 14.1
	 	Term	  	39
	 14.2
	 	Mutual Termination	  	39
	 14.3
	 	Termination by Orphan Medical	  	39
	 14.4
	 	Rights and Obligations on Termination	  	40
	 14.5
	 	Partial Termination	  	40
	 14.6
	 	Sell-Off Period	  	40
	 14.7
	 	Survival	  	41
	 14.8
	 	Assignment of Authorizations	  	41
	 14.9
	 	Rights on Termination for Cause	  	41
	 14.10
	 	No Compensation	  	41
			
	ARTICLE XV	 	 ARBITRATION
	  	41
			
	 15.1
	 	Litigation Rights Reserved	  	41
	 15.2
	 	Arbitration	  	41
	 15.3
	 	Governing Law	  	42
			
	ARTICLE XVI	 	 FORCE MAJEURE
	  	42
			
	 16.1
	 	Events of Force Majeure	  	42
	 16.2
	 	Notice	  	43
	 16.3
	 	Hardship	  	43
			
	ARTICLE XVII	 	 MISCELLANEOUS
	  	43
			
	 17.1
	 	Notices	  	43
	 17.2
	 	Waiver	  	44
	 17.3
	 	Entire Agreement	  	44
	 17.4
	 	Amendment	  	44

  

 iii 

 TABLE OF CONTENTS 
  

					
	 	 	 	  	Page

	 17.5
	 	Headings	  	44
	 17.6
	 	Relationship of the Parties	  	44
	 17.7
	 	Assignment	  	44
	 17.8
	 	Severability	  	44
	 17.9
	 	Publicity	  	45
	 17.10
	 	Counterparts	  	45
	 17.11
	 	LIMITATION OF DAMAGES	  	45

  
 APPENDICES 
  

	
	 Appendix A – Territory

	 Appendix B – Trademark and Patent Rights

	 Appendix C – Product Specifications

	 Appendix D – Standard Operating Procedure for Exchange of Safety Data

	 Appendix E – Quality Agreement

	 Appendix F – Celltech First Commercial Year Forecast

	 Appendix G – Components of Standard Manufacturing Cost and Transfer Price

	 Appendix H – Regulatory Assistance

	 Appendix I – Trademark Use Standards

  
 SCHEDULES 
  

	
	 ORPHAN MEDICAL

	 8.1(e)(ii) – Patent Rights, Trademarks and Other Intellectual Property

	 8.1(e)(iii) – Infringement or Conflict

	 8.1(f)(i) – Contracts

	 8.1(f)(ii) – Default, Breach or Violation

	 8.1(g)(i) – Claims

	 8.1(h) – Required Approvals

  

	
	 CELLTECH

	 8.1(e)(i) – Contracts

	 8.1(e)(ii) – Default, Breach or Violation

	 8.1(f)(i) – Claims

	 8.2(g) – Required Approvals

  

 iv 

 XYREM LICENSE AND DISTRIBUTION AGREEMENT 
  
 This LICENSE AND DISTRIBUTION AGREEMENT (this “Agreement”)
is made and entered into as of October 29, 2003 (“Effective Date”), by and between Orphan Medical, Inc., a corporation having its principal place of business at 13911 Ridgedale Drive, Suite 250, Minnetonka, Minnesota 55305, USA
(together with its Affiliates, “Orphan Medical”), and Celltech Pharmaceuticals, Ltd., a biopharmaceutical company organized under the laws of England having its principal place of business at 208 Bath Road, Slough, Berkshire SL1
3WE, United Kingdom (together with its Affiliates, “Celltech”). 
  
 RECITALS 
  
 WHEREAS, Orphan Medical has developed, patented, registered with the FDA and currently sells the Product (as defined below) in the United States, and wishes to sell the Product to Celltech for distribution in the Territory (as defined
below); 
  
 WHEREAS, Celltech has regulatory and marketing
expertise necessary to review and re-format regulatory pharmaceutical applications and to market ethical pharmaceuticals targeted to specified populations of patients in the Territory; and 
  
 WHEREAS, Celltech wishes to register, package, label, promote, market, sell
and distribute the Product in the Territory, as hereinafter defined, and Orphan Medical wishes to authorize Celltech to do so, all on the terms and conditions set forth herein. 
  
 NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, Orphan Medical and Celltech agree as follows: 
  
 ARTICLE I 
 DEFINITIONS 
  
 “Affiliate” shall mean any corporation or non-corporate
business entity controlled by, controlling or under common control with, a party to this Agreement. For the purpose of this definition, “control” shall mean the direct or indirect ownership or control of at least fifty percent (50%) of the
voting stock of a corporation or a) in the absence of ownership of at least fifty percent (50%) of the voting stock of that corporation, or b) in the case of a non-corporate business entity, if it possesses, directly or indirectly, whether by virtue
of an ownership interest of any kind, by contract or otherwise, the power to direct or cause the direction of the management and policies of the corporation or non-corporate business entity or to elect or cause the election of a majority of the
board of directors or other governing body of such corporation or non-corporate business entity. 
  
 “Adverse Event” means the ICH guideline definition as further defined in Appendix D. 
  
 “API” means the active pharmaceutical ingredient sodium
oxybate contained in the Product. 
  
 “Claims”
shall have the meaning provided in Section 9.1. 

 “Commercial Forecasts” shall have the meaning provided in Section 7.1. 
  
 “Commercially Reasonable Efforts” means all those efforts
that are commercially reasonable under the prevailing circumstances, but in no event will such efforts be less than those that the applicable party would undertake for its own purposes. 
  
 “Components” means the dosing cups and lids, syringe, tamper resistant seal and PIBA included in the pack
issued to customers along with each bottle of Product. 
  
 “Contract Year” means each twelve (12) month period during the Term of this Agreement starting on 01 January and ending on 31 December. 
  
 “Current Good Manufacturing Practices” or “cGMP” means the regulations set forth in 21
C.F.R. Parts 210 - 211, 820 and 21 C.F.R. Subchapter C (Drugs), Quality System Regulations and the requirements thereunder imposed by the FDA, and the equivalent regulations and requirements applicable in the Territory. 
  
 “DEA” means the United States Drug Enforcement
Administration, or any successor thereto, having the administrative authority to regulate the scheduling and distribution of certain drugs in the United States. 
  

“EMEA” means the European Medicines Evaluation Agency or any successor entity which coordinates the scientific review of human
pharmaceutical products under the centralized licensing procedure in the European Union. 
  
 “FDA” means the United States Food and Drug Administration or any successor entity. 
  
 “First Commercial Sale” means the first sale of the Product by or on behalf of Celltech to a wholesaler, distributor or end-user in the
Territory following Registration of the Product in the Territory. 
  
 “ICH” means International Conference on Harmonization of technical requirements for registration and manufacturing of pharmaceuticals for human use as may be amended from time to time. 
  
 “Indemnification Amounts” shall have the meaning provided in
Section 9.1. 
  
 “Indication” means any medical
condition or set of symptoms for the treatment of which a medicinal product is or may be prescribed. 
  
 “Improvements” means any and all inventions or discoveries (including, without limitation, manufacturing, manufacturing processes and
procedures, analytical processes, procedures or methods and analytical results) any route(s) of synthesis, new formulations and/or delivery forms of or with respect to the API and/or Product (other than the current form of the Product as defined
herein), including all information and data relating thereto, whether patentable or not, whether originating from Orphan Medical or from Celltech, including copyrights, trademarks, patents, patent applications, trade secrets, NDAs and Know How.

  

 2 

 “Know How” means data and information regarding toxicology, pharmacology, clinical
trials, analytical methodologies, and use of the Product that is necessary or useful for Celltech to fulfill its obligations hereunder, all of which is proprietary to Orphan Medical. 
  
 “Licensed Indications” means narcolepsy and its associated conditions including without limitation
cataplexy and excessive daytime sleepiness and any other Indication(s) for which Celltech obtains the right to develop the Product pursuant to Section 2.3 hereof. 
  
 “Licensed Intellectual Property” shall have the meaning provided in Section 2.2. 
  
 “Major European Country(ies)” means those countries listed
as such on Appendix A hereto, as such Appendix may be amended from time to time in accordance with Section 2.6 of this Agreement. 
  
 “Manufacturing Know How” means all data, information and materials relating to the manufacture of the Product that is not included in the
Know How. 
  
 “Marketing Authorization” means a
Regulatory Authority approval necessary to commercially promote and distribute the Product for a Licensed Indication in the Territory including where applicable, price and reimbursement approval which must be granted for the Product to be sold in
such country. Marketing Authorization as applied to any country within the Territory does not include the approval of a treatment IND, pre-approval human use trials under a protocol or distribution of a product under an emergency use program, e.g.,
distribution on a Named Patient Basis. 
  
 “Market Sales
Price” means the price for the Product approved by the Regulatory Authority in each country of the Territory, or in countries where pricing is not regulated, the price at which Celltech sells the Product. 
  
 “Minor European Country(ies)” means those countries listed
as such on Appendix A hereto, as such Appendix may be amended from time to time in accordance with Section 2.6 of this Agreement. 
  
 “Named Patient Basis” means any distribution of Product by Orphan Medical or Celltech, as its designee, for sale prior to Registration of
the Product through approval by a Regulatory Authority in the Territory or as otherwise allowed by local law. 
  
 “NDA” means a New Drug Application filed by Orphan Medical with the FDA or any equivalent successor application for approval to
commercially promote and distribute the Product in the United States. 
  
 “Net Sales” means for purposes of calculating the payments payable by Celltech to Orphan Medical pursuant to Sections 4.1, 4.2 and 4.3 of this Agreement, the gross sales prices received by Celltech, its Subdistributors or
Sublicensees from sales of the Product, not including Product samples, sold by or for Celltech, its Subdistributors or Sublicensees to independent third parties in the Territory, after in each case, deduction of the following items allowed, given,
granted, paid or borne by or for Celltech, its Subdistributors or Sublicensees with respect to sales of the Product: 
  
 (a) all bona fide promotional, cash, trade and quantity discounts and rebates; 
  

 3 

 (b) all bona fide allowances to end users or credits (whether in the form of a credit or free Product) on
account of price adjustments, rejection or return, recalls, charge backs or governmental program rebates (including without limitation to managed care organizations); 
  
 (c) all sales, consumption, excise and any other taxes, tariffs, duties or government charges (including any tax such as
value added or similar tax or government charge other than income tax) with respect to sales of the Product; and 
  
 (d) any charges for freight or insurance. 
  
 For avoidance of doubt, in order to avoid any double counting when determining Net Sales (i) Net Sales shall not include any royalties, proceeds or other
amounts paid to Celltech by any Sublicensee and (ii) if the gross sales price received by a Subdistributor from one or more sales has been counted, then Net Sales shall not include any royalties, proceeds or other amounts that are paid by such
Subdistributor to Celltech in connection with such sales. 
  
 “Option Country” means a country listed as such on Appendix A hereto which is not currently located in the Territory and which Celltech has the option, in its sole discretion, to include in the Territory, if after
the Effective Date, such Option Country joins the European Union or European Free Trade Area. 
  
 “Orphan Drug Designation” means designation by the EMEA as an orphan drug, a drug for a specified rare disease or condition, or the equivalent designation by a Regulatory Authority of any country of
the Territory. 
  
 “Patent Rights” means European
patent Number EP 1140061 and any other patents listed on Appendix B hereto, the inventions described and claimed therein relating to the Product and any application for letters patent relating thereto, including, without limitation a
continuation application, a continued prosecution application, a continuation in part application or a divisional application, and any supplementary protection certificates, extensions, substitutions, confirmations, divisions, continuations,
continuations-in-part, patents issuing thereon and reissues or re-examinations thereof (each which shall be automatically incorporated in and added to this Agreement and shall periodically be added to Appendix B attached to this Agreement and
made a part hereof). 
  
 “Person” means any
individual, general or limited partnership, corporation, limited liability company, association, business trust, joint venture, Regulatory Authority, business entity or other entity of any kind or nature. 
  
 “Product” means Orphan Medical’s proprietary
pharmaceutical product Xyrem containing the API as its active ingredient in bulk, unlabeled bottles, for use as a treatment for the Licensed Indications and all Components therefor unless Celltech shall elect to source such Components from a Third
Party as contemplated by Section 2.1(d). 
  
 “Product
Specifications” means specifications of the Product as approved in the Marketing Authorizations including specifications of secondary packaging, or as otherwise agreed upon by Orphan Medical and Celltech. The Product Specifications
contained in the NDA as of the Effective Date are attached as Appendix C hereto. 
  

 4 

 “Proprietary Information” shall mean the terms and provisions of this Agreement and all
non-public information or data relating to the Product and the subject matter hereof first communicated by or on behalf of one party to the other, whether in writing or orally, including without limitation, all scientific, clinical, commercial,
financial and business information and data, know-how, compilations, formulae, processes, plans, technical information, new product information, compounds, formulations, methods of product-delivery, test procedures, product samples, specifications
and other information or data. 
  
 “Registration”
shall have occurred and shall continue in each country in the Territory when the Marketing Authorization required in respect of such country shall have been issued and shall continue to be effective. 
  
 “Regulatory Authority” means the EMEA and each other
regulatory and drug scheduling authority equivalent to the FDA and DEA in the Territory or a country in the Territory, which has responsibility for scheduling drugs and approving Marketing Authorizations. 
  
 “Steering Committee” means the joint committee established
pursuant to Section 3.9. 
  
 “Subdistributors”
means any subdistributor (exclusive of pre-wholesalers, wholesalers and Sublicensees) of the Product in the Territory appointed by Celltech from and after the Effective Date pursuant to this Agreement. 
  
 “Sublicensee” means any Third Party who is licensed by
Celltech to promote, market, sell and distribute the Product in the Territory in consideration of the payment to Celltech of a purchase price for the Product and royalties on sales of the Product to Third Parties. 
  
 “Term” shall have the meaning provided in Section 14.1
hereof. 
  
 “Territory” means the Major European
Countries and the Minor European Countries set forth in Appendix A, as such Appendix may be amended from time to time pursuant to Section 2.6 of this Agreement. 
  
 “Third Party” means a Person who or which is neither a party to this Agreement nor an Affiliate thereof.

  
 “Trademark” means the trademark set forth in
Appendix B. 
  
 “Transfer Price” means the
price(s) Orphan Medical charges Celltech for Product on a per bottle and per Component basis; provided, however, that the Transfer Price shall not exceed * for the Product, exclusive of Components plus, when Components are being
purchased, 100% of Orphan Medical’s cost of Components. The constituents comprising Orphan Medical’s standard manufacturing cost are listed on Appendix G, which also shows a Transfer Price of * for the Product including Components
as of the date hereof. 
  

 5 

 “Weighted Average List Price” means Celltech’s total annual gross sales receipts
for the Product received from Celltech’s customers in the Territory calculated based on the Market Sales Price, divided by the quantity of Product sold in the Territory. 
  
 ARTICLE II 
 APPOINTMENT 
  
 2.1 Appointment as
Distributor. Subject to the terms and conditions of this Agreement, Orphan Medical hereby appoints Celltech, and Celltech accepts such appointment, as Orphan Medical’s exclusive distributor of the Product in the Territory. During the Term
of this Agreement, Celltech shall purchase all of its requirements of the Product from Orphan Medical as the sole supplier except as follows: 
  
 (a) Celltech Manufacturing. Orphan Medical agrees to discuss with Celltech the feasibility and commercial viability of transferring the manufacture
of the Product to Celltech’s FDA approved facilities or qualifying and registering Celltech as a back-up manufacturer for the Product for the Territory and/or for the rest of the world. 
  
 (b) Third Party Manufacturing. If Orphan Medical is unable to
manufacture or supply the quantity of Product ordered by Celltech in accordance with this Agreement for any reason whatsoever, including, without limitation, by reason of an event described in Section 16.1 (Events of Force Majeure), Celltech shall
have the right at its sole election to (A) take over the manufacture of the Product or appoint a Third Party manufacturer to fulfill Orphan Medical’s manufacturing and supply obligations under this Agreement thereafter through the remaining
Term of this Agreement and/or (B) purchase the API from Orphan Medical and itself convert, or appoint a Third Party manufacturer to convert, the API into Product through the Term of the Agreement; provided, however, such right shall be
exercisable only if (1) Orphan Medical’s inability to manufacture or supply the Product could reasonably be expected to result in a period of time of at least three (3) months during which less than fifty percent (50%) of Product ordered
pursuant to Celltech’s last firm purchase order would be available to Celltech for commercial sale, (2) Celltech provides reasonable evidence of its ability to procure a Third Party manufacturer or take over the manufacture of the Product or
the API more rapidly than Orphan Medical could restart production and supply of Product, and (3) Orphan Medical’s inability to manufacture or supply Product did not result, wholly or in part, from a breach by Celltech of its obligations
hereunder. Orphan Medical shall provide Celltech with all reasonable assistance in taking over or obtaining and qualifying a Third Party manufacturer, including without limitation, licensing its Manufacturing Know-How to Celltech and/or such Third
Party manufacturer solely for the purpose of manufacturing the API and/or the Product pursuant to this Section 2.1(b). 
  
 (c) Price for Manufacturing Changes. In the event Celltech shall manufacture Product or API or cause Product or API to be manufactured pursuant to
this Agreement, a manufacturing royalty, transfer price or price of manufacturing services to Orphan Medical, and any other related terms therefor, shall be negotiated in good faith. 
  
 (d) Component Sourcing. Celltech shall be permitted at any time during the Term on sixty (60) days prior written
notice to Orphan Medical to cease purchasing some or all Components from Orphan Medical and purchase some or all of the Components directly from 
  

 6 

 Orphan Medical’s suppliers or qualify another Third Party(ies) to supply Components; provided that, subject
to Sections 7.7 and 7.12, Celltech must purchase all Components delivered by Orphan Medical pursuant to a firm order regardless of whether such delivery is made after Celltech delivers notice to Orphan Medical of its intent to purchase the
Components from Orphan Medical’s suppliers or another Third Party(ies). Celltech shall bear any and all costs associated with qualifying any Third Party(ies) to supply Components pursuant to this Section 2.1(d); provided that if
Orphan Medical desires to purchase the same Components from such Third Party(ies) as Celltech is purchasing, then Orphan Medical and Celltech shall each bear fifty percent (50%) of any such costs. 
  
 2.2 License Grant. Subject to the terms and conditions of this
Agreement, Orphan Medical hereby grants Celltech an exclusive nontransferable, royalty-bearing right and license (with the right of sublicense, as specifically set forth herein), to use the NDA, Know How, Trademark, Patent Rights and all
Improvements and Proprietary Information of Orphan Medical related thereto or to the Product together with the goodwill associated therewith (the “Licensed Intellectual Property”) during the Term, solely in the Territory, and solely
for the purposes of (i) preparing applications for Marketing Authorizations and obtaining and maintaining Registrations and packaging, labeling, promoting, marketing, selling and distributing the Product under the Trademark in the Territory solely
for the Licensed Indications and (ii) exercising its other rights under this Agreement including those provided in Articles X and XI hereof and making or having made API and/or Product but only as provided in Section 2.1. Except as set forth in
Section 6.8, no license is granted to Celltech hereunder for any rights to market the Product for other Indications. Except as provided in Section 14.6, the license set forth above shall terminate automatically upon termination or expiration of this
Agreement. Subject only to the foregoing express license grant and its other rights as herein provided, Celltech shall not have and shall not assert any claim, right, title or interest in or to the Licensed Intellectual Property. 
  
 2.3 Right of First Negotiation for Other Indications. 
  
 (a) Negotiation Notice. If, during the Term of this Agreement, Orphan
Medical desires to pursue further development of the Product in the Territory for one or more Indications other than the Licensed Indications, or in the Option Countries or in Australia for the Licensed Indications or one or more Indications other
than the Licensed Indications, Orphan Medical shall provide written notice to Celltech (the “Negotiation Notice”) of its intent to negotiate an agreement therefor. The Negotiation Notice shall identify the relevant country or
countries and Indications. Delivery of a Negotiation Notice shall create a mutual obligation to negotiate in good faith on an exclusive basis for the grant to Celltech of exclusive rights to the Product for the specified countries for such
Indication(s). If no response is received within ninety (90) days after delivery of the Negotiation Notice to Celltech, the offer shall be deemed declined, and Orphan Medical may then negotiate with any Third Party for the grant of any license for
the Product for such countries for such Indication(s) subject, however, to the last sentence of Section 2.3(b). 
  
 (b) Procedure of Negotiations. The parties shall have ninety (90) days from the date Orphan Medical receives Celltech’s response to the
Negotiation Notice to negotiate in good faith (and on a confidential basis), and enter into a letter of intent, term sheet or final agreement with regard to, as applicable, Celltech’s distribution of the Product in the Territory for 

 

 7 

 the new Indication(s) or in the Option Countries or Australia for the Licensed Indications or one or more Indications
other than the Licensed Indications. In the event that (i) Celltech shall have failed to have responded to the Negotiation Notice within the 90-day period provided in paragraph (a) above or (ii) within the 90-day period provided in this paragraph
(b) Orphan Medical and Celltech have not entered into such letter of intent, term sheet or final agreement, Orphan Medical shall have no further obligation to undertake or continue negotiations with Celltech for such license, and Orphan Medical
shall be free to commence negotiations for a license to the Product for such countries for such Indication(s) with any Third Party subject to the following: (i) if a letter of intent, term sheet or final agreement with a Third Party shall not have
been signed by Orphan Medical and such Third Party within two hundred seventy (270) days of the termination of Celltech’s right of first negotiation, then Celltech’s right of first negotiation shall again become effective on the terms
herein provided and (ii) without Celltech’s prior written consent, the terms and conditions agreed by Orphan Medical with such Third Party may not be in the aggregate materially more favorable to such Third Party than those last offered to
Celltech. 
  
 (c) Option Countries. If Orphan Medical shall
determine to enter into a license for the Product with a Third Party in an Option Country upon expiration of Celltech’s right of first negotiation pursuant to Section 2.3(b) above, such license shall contain a provision automatically
terminating such License should such country subsequently join the European Union or European Free Trade Area during the Term and Celltech shall have exercised its Option under Section 2.6 as to such country. 
  
 (d) No Trademark License. If pursuant to this Section 2.3 Orphan
Medical licenses to a Third Party the Product in the Territory for one or more Indications other than the Licensed Indications or in the Option Countries or Australia for one or more Indications other than the Licensed Indications, then such Third
Party shall be obligated to market the Product under a trademark different from the Product Trademark and Orphan Medical shall not grant, license or otherwise transfer to such Third Party any rights to the Trademark or otherwise permit any use of
the Trademark by such Third Party. 
  
 2.4
Subdistributors/Sublicensees. Celltech may appoint Subdistributors and Sublicensees with the prior written approval of Orphan Medical, which approval shall not be unreasonably withheld. No such appointment or delegation shall relieve Celltech
from any obligations hereunder, and each agreement with a Subdistributor or Sublicensee shall include terms ensuring the protection of Orphan Medical’s rights under this Agreement. Celltech shall guarantee and be responsible for the making of
all payments due, and the making of reports required under this Agreement by its Subdistributors and Sublicensees, and their compliance with all applicable terms of this Agreement. All agreements between Celltech and its Subdistributors and
Sublicensees shall include a provision prohibiting the further appointment of Subdistributors or Sublicensees, as the case may be, and a provision terminating the Subdistributor or Sublicensee agreement to the extent such agreement relates to the
Product in the Territory upon termination of this Agreement for any reason. 
  
 2.5 Sales Outside the Territory. Except as otherwise set forth in this Agreement, Celltech shall not distribute, sell or otherwise provide the Product outside of the Territory and shall not solicit customers
for the Product outside the Territory or establish any office through 
  

 8 

 which orders are solicited or any depot at which inventories of the Product are stored outside the Territory. Celltech
shall not sell the Product to customers outside the Territory, provided that nothing herein shall preclude Celltech from selling the Product to any customer, wherever located, who purchases Product with a view to its use within any country of the
Territory. 
  
 2.6 Option to Expand the Territory. If,
after the Effective Date, an Option Country joins the European Union or European Free Trade Area, Celltech, in its sole discretion, may add such Option Country to the Territory and may designate such Option Country as a Major European Country or a
Minor European Country. Celltech shall notify Orphan Medical of its decision within thirty (30) days after the date Celltech first learns of such country joining the European Union or European Free Trade Area, and, if Celltech so chooses to add such
Option Country to either the Major European Countries or Minor European Countries, then Appendix A hereto shall be amended to so reflect such addition. 
  

2.7 Competitive Product. Orphan Medical acknowledges that (i) Celltech has developed and is marketing methylphenidate in certain countries
within the Territory for Indications other than the Licensed Indications, but that methylphenidate is occasionally used on an off-label basis to treat the Licensed Indications; (ii) Celltech is marketing dexedrine in the United Kingdom for the
Licensed Indications; and (iii) Celltech will be marketing Equasym IR in France for the Licensed Indications. With the exception of the off-label use of methylphenidate in the Territory, dexedrine in the United Kingdom, and Equasym IR in France,
Celltech shall not, for five (5) years from the Effective Date of this Agreement, either directly or indirectly through subdistributors, sublicensees or otherwise, develop, manufacture, promote, market or distribute products in the Territory that
are competitive with the Product; provided, however, nothing herein shall prohibit Celltech from acquiring, by stock purchase, asset purchase or merger any company, or division of a company, that is developing, marketing,
manufacturing, promoting or distributing a competitive product where the annual sales (or in the case of a product in development, the projected sales) of such competitive product in the Territory are less than twenty percent (20%) of such
company’s or division’s total annual sales. For purposes of this Section 2.7, a competitive product shall be one that: (a) is approved for prescription for a Licensed Indication or (b) is used off-label for a Licensed Indication and
such off-label sales comprise more than twenty percent (20%) of such product’s sales in the Territory or more than twenty percent (20%) of the sales of the Product in the Territory. 
  
 ARTICLE III 
 REGULATORY APPROVALS; 
 COMPLIANCE WITH LAWS AND REGULATIONS 
  
 3.1 Marketing Authorizations. Celltech shall prepare and submit to
Orphan Medical, (i) within sixty (60) days of the Effective Date, a written plan for obtaining approval from the EMEA to commercially promote and distribute the Product for the cataplexy Licensed Indication and (ii) within one hundred twenty (120)
days of the Effective Date, a written plan for obtaining approval to commercially promote and distribute the Product for the cataplexy Licensed Indication from the Regulatory Authority of each country in the Territory not covered by an EMEA
Registration. On the basis of Orphan Medical’s NDA and the Know How and related Proprietary Information delivered pursuant to Section 3.2, Celltech shall collect, assemble, organize and format all necessary components required to apply for such
approvals, and shall 
  

 9 

 submit such materials to the appropriate Regulatory Authorities in accordance with Section 3.2. Celltech shall maintain,
at its own expense, the Registrations and other authorizations necessary to import, label, promote, market, sell and distribute the Product in the Territory. Orphan Medical shall provide, at its own cost and expense (but subject to the limitations
set forth in Section 3.2), reasonable assistance to Celltech in the acquisition of such Registrations, including without limitation, the services set forth on Appendix H hereto. All applications for Marketing Authorizations for the Product
shall be submitted in the name of Celltech and all Marketing Authorizations for the Product shall be assigned to Orphan Medical upon termination of this Agreement for any reason. Celltech shall ensure that all pages of documents submitted to
Regulatory Authorities for the purpose of obtaining Registrations and Marketing Authorizations shall be coded as confidential. 
  
 3.2 Regulatory Timelines. (a) Within thirty (30) days of the Effective Date, Orphan Medical shall (i) transfer the Orphan Medical Drug Designation
in the Territory from IDIS World Medicines to Celltech, and (ii) provide Celltech with the NDA and the Know How and the related Proprietary Information to enable Celltech to prepare and timely file the applications to commercially promote and
distribute the Product for the cataplexy Licensed Indication in the Territory. Celltech shall use its Commercially Reasonable Efforts to cause a pre-submission meeting to be held with the EMEA in respect of the cataplexy Licensed Indication within
one hundred eighty (180) days of the Effective Date. Within thirty (30) days of such meeting with the EMEA, Celltech shall report to Orphan Medical about the content of such meeting and advise Orphan Medical as to whether additional data or
documentation or additional action is required or deemed reasonably necessary by Celltech to obtain approval from the EMEA to commercially promote and distribute the Product for the cataplexy Licensed Indication. If additional data or documentation
or additional action is required or deemed reasonably necessary by Celltech to obtain such approval and Orphan Medical has or could readily produce such data or documentation or take such additional action, Orphan Medical shall so provide the
additional data or documentation or take the additional action at its sole cost and expense; provided, however, that in the event the cost of any single study or other report required by the EMEA or deemed reasonably necessary by
Celltech shall exceed * or the aggregate cost of all studies or other reports required by the EMEA or deemed reasonably necessary by Celltech shall exceed * , Celltech and Orphan Medical shall meet and discuss in good faith the apportionment of such
costs between them. Provided that Orphan Medical’s NDA and other relevant Know How and related Proprietary Information are deemed reasonably sufficient by Celltech, Celltech shall, at its own expense, file the application for approval of the
Product by the EMEA as an orphan drug. 
  
 (b) Following approval
from the EMEA to commercially promote and distribute the Product for the cataplexy Licensed Indication, Celltech shall use Commercially Reasonable Efforts to obtain Registration of the Product for the cataplexy Licensed Indication (i) in the Major
European Countries no later than December 31, 2005 (the “Registration Date”) and (ii) in the other countries in the Territory within such time frames as are consistent with the regulatory plan submitted by Celltech to Orphan Medical
as provided in Section 3.1; unless, in any such case, additional data or documentation or additional action is required, in which case, the timeframe shall be extended by the time required to generate the additional data or documentation or take the
additional action. Where a Regulatory Authority requires additional data or documentation or additional action that is not within Orphan Medical’s sole obligation as delineated in paragraph (a) above and that neither party has or could readily
produce or which 
  

 10 

 cannot readily be taken by either party, the parties shall negotiate in good faith the terms upon which such data or
documentation should be generated or actions taken by either party, if at all, or failing agreement, to terminate this Agreement in so far as it relates to a country in the Territory not a member of the European Union or the European Free Trade
Area. 
  
 (c) Anything herein to the contrary notwithstanding, (i)
except as provided in paragraphs (a) and (b) above, in connection with providing additional data and documentation or taking additional actions pursuant to this Section 3.2, each party shall be responsible for all costs and expenses of its
respective employees, agents, contractors, sublicensees and subdistributors, and (ii) no party shall be obligated to conduct any clinical trials after the Effective Date. 
  
 (d) Following the development by Orphan Medical of a supplemental NDA for the excessive daytime sleepiness Licensed
Indication, which such supplemental NDA shall be developed by Orphan Medical as soon as practicable after the Effective Date, a copy thereof shall be delivered to Celltech to enable it to prepare an application to the EMEA for approval to
commercially promote and distribute the Product in the Territory for the excessive daytime sleepiness Licensed Indication. Such application shall be filed by Celltech no later than the later of (i) issuance of the license to Celltech by the EMEA for
the cataplexy Licensed Indication or (ii) one hundred eighty (180) days after Orphan Medical delivers such supplemental NDA to Celltech, unless additional data or documentation or additional action is required from Orphan Medical or a Third Party,
in which case the one hundred eighty (180) days shall be extended by the time required to generate the additional data or documentation or take the additional action. 
  
 3.3 Other Approvals. Celltech undertakes and covenants that as soon as reasonably practicable following the Effective
Date it shall take all other actions to obtain and maintain during the Term all other approvals, licenses and permits necessary to import, promote, market, sell and distribute the Product in the Territory. 
  
 3.4 Return of Initial Payment. In the event that following and as a
result of the pre-submission meeting with the EMEA, the parties mutually agree that it is not possible or commercially viable under the prevailing circumstances to obtain Registration for the Product in the Major European Countries, the parties may
agree to terminate this Agreement, and such termination shall be subject to the terms of Article 14. Upon any such termination, Orphan Medical shall refund to Celltech a portion of the initial $2.5 million US Dollar payment due on the Effective Date
under Section 4.1(a). Such refund shall be $1.25 million US Dollars within ninety (90) days of Celltech’s providing to Orphan Medical input relating to the pre-submission meeting pursuant to Section 3.2, and $750,000 US Dollars ninety (90) days
thereafter. If the parties do not mutually agree that Registration in the Major European Countries is not possible or commercially viable under the prevailing circumstances, then they shall submit the matter to arbitration in accordance with the
provisions of Section 15.2 of this Agreement. 
  
 3.5 Product
Changes. Orphan Medical shall give Celltech ninety (90) days prior written notice of any major formulation or packaging change to the Product being requested or required by the FDA, or any other U.S. Regulatory Authority, whenever such change
affects a Registration in any country within the Territory. Orphan Medical may change the Product, or analytical test methods as it deems appropriate, provided Orphan Medical continues to supply Product conforming to the Product Specifications then
in effect until such times as the Marketing 
  

 11 

 Authorizations are amended to reflect such changes. In the event of such changes, Celltech shall be solely responsible
for additional submissions and/or regulatory updates which may be required by the Regulatory Authorities in the Territory, provided that all necessary data and information shall be furnished by Orphan Medical at Orphan Medical’s expense
for such purposes, and provided; further that in no event shall Celltech’s failure to obtain any required amendments to the Marketing Authorizations to reflect such additional submissions and/or regulatory updates, relieve Orphan
Medical of its obligation to supply Product conforming to the Product Specifications. In the event a Regulatory Authority in any country in the Territory requires a formulation or packaging change to the Product, Orphan Medical and Celltech shall
cooperate to develop a mutually agreeable plan to address the regulatory requirement, and, if necessary, to include the production of separate lots, at Celltech’s expense, for the Territory. In the event Orphan Medical and Celltech mutually
agree it is not commercially reasonable to meet such requirements, Celltech shall cease promoting, marketing, selling and/or distributing the Product in that country in the Territory and shall promptly terminate the Registrations in such country. If
the parties are in disagreement as to whether it is commercially reasonable to meet such requirements, then they shall submit the matter to arbitration in accordance with the provisions of Section 15.2 of this Agreement. 
  
 3.6 Clinical Trials. The parties shall keep one another fully and
currently informed as to all tests and trials that they intend to carry out for purposes of compliance with regulatory requirements in the Territory or that might affect Marketing Authorization applications or Registrations in the Territory. The
parties shall cooperate in the design of such tests and trials in order to ensure to the maximum possible extent that duplication of effort shall be avoided, and that the results shall be suitable for filing with the Regulatory Authorities in the
Territory and shall otherwise be useful for purposes of meeting all applicable regulatory requirements. Without limiting the generality of the foregoing, the parties shall use their Commercially Reasonable Efforts to ensure that all clinical trials
undertaken after the Effective Date, if any, shall be designed and conducted in accordance with good clinical practices and good laboratory practices as established for both the United States and the European Union. 
  
 3.7 Compliance With Applicable Laws. Celltech shall comply with all
applicable laws and regulations of each country in the Territory (including, without limitation, any laws or regulations in the Territory governing the distribution of a scheduled drug, as designated under regulations promulgated by the DEA).
Celltech shall also comply with all U.S. laws applicable to the Registration, promotion, marketing, sale and distribution of the Product in the Territory, including but not limited to U.S. Export Administration Regulations, the US Foreign Corrupt
Practices Act and all regulations promulgated by the DEA. Celltech shall comply with all Marketing Authorizations issued in the Territory. 
  
 3.8 Approved Product Packaging and Labeling; Relevant Testing. After the Product receives a Marketing Authorization in any country of the
Territory, Celltech shall package and label the Product and shall include all required labeling for Product sold in such country(ies). For all orders submitted by Celltech after Registration is received in a particular country, Orphan Medical shall
supply to Celltech unlabeled bottles, and final labeling and packaging of Product for such country(ies) shall be completed by Celltech. After the Product receives Marketing Authorization in a country in the Territory, Celltech shall be solely
responsible for all final release testing in such country(ies) and for ensuring in such country(ies) that the Product labeling 
  

 12 

 and packaging complies with the Marketing Authorizations and all other applicable laws of each such country in the
Territory. Celltech shall provide Orphan Medical with copies of all foreign language labels. To the extent permitted by applicable laws and regulations in each country in the Territory, all labels shall identify Orphan Medical as the manufacturer of
the Product for Celltech. 
  
 3.9 Steering Committee.
Within a reasonable period of time after the Effective Date, Orphan Medical and Celltech shall form a Steering Committee made up of commercial and technical employees from both companies that shall have certain decision-making authority, and provide
oversight for the administration of this Agreement. Each party shall maintain two (2) members on the Steering Committee with other members added as needed. The parties shall each select one of its representatives to serve as a co-chairperson of the
Steering Committee. The Steering Committee shall have the authority to conduct the following activities and such other activities as may be agreed to in writing by the parties: (a) review ongoing regulatory issues, (b) review the medical aspects of
standards of care in the Territory, (c) review clinical developments across territories, (d) review marketing campaigns and new marketing plans, (e) review sales activities and results, (f) review aspects of Product manufacturing campaigns and
Product forecasts, consignment and non-consignment inventory stocks and ordering, and (g) review the arrangement for distributing Product on a Named Patient Basis. In the event and to the extent that the Steering Committee is unable to come to a
consensus on any matter relating to the development or manufacture of the Product or the Registration, packaging, labeling, promoting, marketing, sale or distribution of the Product outside the Territory, the views of the Orphan Medical Steering
Committee members shall prevail. In the event and to the extent that the Steering Committee is unable to come to a consensus on any matter relating to the Registration, packaging, labeling, promoting, marketing, sale or distribution of the Product
within the Territory, the views of the Celltech Steering Committee members shall prevail. Notwithstanding the foregoing, in the event a particular matter for which there is no consensus of the Steering Committee could, in the good faith judgment of
the party who does not have the ultimate decision making authority as to such matter (as provided in the previous two sentences), materially affect the rights or obligations under this Agreement of such party, Orphan Medical and Celltech agree to
use Commercially Reasonable Efforts to resolve the matter in a manner which will minimize the impact on such rights or obligations of such party. During each Contract Year, the parties shall hold at least four (4) regular meetings of the Steering
Committee. Members of the Steering Committee may participate in meetings of the Steering Committee in person or by conference telephone call. At least one (1) of the four (4) Steering Committee meetings shall be conducted in-person. Employees of
each party who are not members of the Steering Committee may attend meetings of the Steering Committee as required. In-person Steering Committee meetings shall alternate between Orphan Medical’s designated facility and a facility designated by
Celltech. The co-chairpersons of the Steering Committee shall alternate responsibility for the preparation of minutes setting forth discussions made at each committee meeting, with the Orphan Medical Chairperson preparing minutes for the first
Steering Committee meeting; provided, however, that such minutes shall not become official until agreed upon by both co-chairpersons. 
  

 13 

 ARTICLE IV 
 ROYALTIES AND MILESTONE PAYMENTS 
  
 4.1 Milestone Payments. In consideration of the rights and licenses granted hereunder, Celltech shall pay to Orphan Medical milestone payments totaling * US Dollars according to the following schedule: 
  
 (a) $2,500,000 US Dollars on the Effective Date. 
  
 (b) * US Dollars upon filing of cataplexy Marketing Authorization application
with the EMEA. 
  
 (c) * US Dollars upon approval by the EMEA to
commercially promote and distribute the Product for the cataplexy Licensed Indication. 
  
 (d) * US Dollars upon pricing approval for the cataplexy Licensed Indication in France provided the price approved (ex works) is at least 115 Euros per 180 ml bottle. 
  
 (e) * US Dollars upon delivery to Celltech by Orphan Medical of supplemental
NDA package for the excessive daytime sleepiness Licensed Indication. 
  
 (f) * US Dollars upon approval by the EMEA to commercially promote and distribute the Product for the excessive daytime sleepiness Licensed Indication. 
  

(g) * US Dollars upon first complete Contract Year in which Celltech’s and its Subdistributors annual Net Sales in the Territory exceed £10
million. 
  
 (h) * US Dollars upon first complete Contract Year in
which Celltech’s and its Subdistributors annual Net Sales in the Territory exceed £15 million. 
  
 (i) * US Dollars upon first complete Contract Year in which Celltech’s and its Subdistributors annual Net Sales in the Territory exceed £20
million. 
  
 4.2 Royalty. (a) In consideration of the
license granted by Orphan Medical hereunder, Celltech shall pay Orphan Medical a quarterly royalty of * on Net Sales of the Product. The royalty rate shall be reduced to * as of the date when Celltech ceases to have the exclusive right in the
Territory, enforceable against Third Parties, to promote, market and sell for the Licensed Indications products containing sodium oxybate as an active pharmaceutical ingredient, because of the expiration or termination in the Territory of Patent
Rights and/or regulatory exclusivity based on the Product’s Orphan Drug designation in the Territory. The royalty rate shall be further reduced to * if there is subsequent competition by a generic product for the Product in the Territory.

  
 (b) If (i) Orphan Medical licenses the Product in the
Territory to a Third Party for one or more Indications other than the Licensed Indications pursuant to Section 2.3(b), and (ii) the Product licensed in the Territory to such Third Party by Orphan Medical is being used off-label for a Licensed
Indication, and (iii) Celltech can demonstrate that such off-label sales results in material erosion of the Product’s sale price in the Territory and/or a material loss of 
  

 14 

 Product sales by Celltech for Licensed Indications in the Territory, then regardless of whether the * royalty rate is in
effect, the parties shall negotiate in good faith a reduction in the royalty rate to appropriately compensate Celltech for such erosion of sales price and/or sales. As part of its demonstration of such material erosion and/or material loss of sales,
Celltech shall obtain at its expense, and furnish to Orphan Medical, a report compiled by a recognized market research company having substantial expertise in the pharmaceutical industry, which sets forth both the sales of the Product and the
off-label sales of the Third Party product in the Territory or sets forth other relevant information demonstrating that Celltech has lost material Product sales or has suffered a material price reduction for the Product due to such off-label sales
of the product licensed to the Third Party. 
  
 4.3 Minimum
Royalty Requirement. Commencing with the Contract Year in which the First Commercial Sale in a Major European Country occurs, if the royalties payable pursuant to Section 4.2 shall be less than the amounts set forth in this Section 4.3, then
Celltech shall pay such additional royalty amounts to Orphan Medical so that Orphan Medical shall have received aggregate royalty payments with respect to Net Sales of the Products in the Territory equal to the following minimum amounts (reducing
the minimum for the first year proportionally for the days therein prior to the date of the First Commercial Sale); provided, however that the following minimum royalty amounts shall be adjusted by written agreement of the parties
after the Effective Date as appropriate to take into account any royalty rate reductions determined in accordance with Section 4.2(b): 
  

							
	Minimum Royalty Payment (£)
	 Year
	  	*	  	*	  	*
	 1
	  	*	  	*	  	*
	 2
	  	*	  	*	  	*
	 3
	  	*	  	*	  	*
	 4
	  	*	  	*	  	*
	 5-10 and 11+
	  	*	  	*	  	*

  
 For the avoidance of
doubt, the parties acknowledge and agree that the minimum royalty payment described in this Section 4.3 shall not be payable with respect to any sales made by Celltech on a Named Patient Basis. 
  
 4.4 Royalty and Milestone Payments. Unless otherwise agreed by Orphan
Medical in writing, all milestone payments set forth in Section 4.1 shall be payable within thirty (30) days after achievement of the relevant milestone, except for the initial $2.5 million payment due on the Effective Date under Section 4.1(a),
which shall be due and payable by Celltech no later than five (5) days after the Effective Date. Royalty payments shall be paid within forty-five (45) days from the end of each calendar quarter after the date of First Commercial Sale and any
additional royalty amounts payable as stated in Section 4.3 shall be paid within forty-five (45) days of the end of each Contract Year. All payments shall be made in United States Dollars by wire transfer to a USA bank designated by Orphan Medical.
Any overdue payment from Celltech to Orphan Medical under this Agreement shall accrue interest at the rate of 3/4% per month or the highest rate allowed by law, whichever is less. Orphan Medical shall have the right to recover its reasonable
collection costs and expenses (including attorneys’ fees) for late payments. 
  

 15 

 4.5 Exchange Rates. For purposes of determining the amount of Net Sales and the amount of
royalties payable pursuant to Section 4.2 during any calendar quarter, the total of all sales in each currency during such quarter shall be converted into US Dollar currency at the average daily exchange rate for such calendar quarter as reported by
oanda.com or, if such website is not available, the Wall Street Journal. For purposes of determining the minimum royalty amount for each Contract Year as provided in Section 4.3, the amounts set forth therein shall be converted into US dollar
currency at the average daily exchange rate for such Contract Year as reported by oanda.com or, if such website is not available, The Wall Street Journal. 
  
 4.6 Taxes. Celltech shall be entitled to deduct from royalties paid hereunder the amount of any withholding taxes or other taxes, levies or charges
required to be withheld by Celltech, to the extent Celltech pays to the appropriate governmental authority on behalf, and for the account of, Orphan Medical such taxes, levies or charges. Celltech shall use reasonable efforts (including making, or
assisting Orphan Medical in making, any relevant application to any tax authority) to minimize any such taxes, levies or charges which are required to be withheld by Celltech from royalties paid hereunder and paid on behalf of Orphan Medical by
Celltech. Celltech shall promptly deliver to Orphan Medical proof of payment of all such taxes, levies and other charges, together with copies of all communications from or with such governmental authority with respect thereto. 
  
 4.7 Reports. Each royalty payment made by Celltech hereunder shall be
accompanied by a report showing all revenue generated by sales of the Product to Third Parties (including all sales by Subdistributors and Sublicensees) during the immediately preceding quarter, the computation of Net Sales, and the calculation of
royalty payments due for such quarter, all on a country-by-country basis. If actual Net Sales of any Subdistributor or Sublicensee for that quarter is unavailable at the time such quarterly report is due, Celltech shall include in its report for
that quarter a good faith estimate of such Net Sales, and an appropriate adjustment for the difference between the actual and estimated Net Sales shall be made in the report for the following quarter, with a corresponding adjustment in the amount of
royalties payable in respect of that quarter. 
  
 4.8 Books and
Records; Audit. Celltech shall keep for at least three (3) years or such longer period as may be required by law following the end of the calendar year to which they pertain, accurate and complete records showing all sales of the Product by
Celltech and its Subdistributors and Sublicensees. Such records shall include all information reasonably necessary to verify the total amount and computation of earned royalties hereunder, and shall be open to inspection and audit, during reasonable
business hours, to the extent necessary to verify the amount of such royalties. Such inspection and audit shall be conducted at the request and expense of Orphan Medical by an independent Certified Public Accountant appointed by Orphan Medical. Such
inspection and audit shall be made not more often than once in each Contract Year. Such Certified Public Accountant shall undertake a confidentiality obligation to Celltech permitting it to disclose only to Orphan Medical the amount of the royalties
due hereunder, and no other information. Orphan Medical shall bear the costs of any such inspection and audit; provided that if any inspection and audit reveals an underpayment of more than five percent (5%), Celltech shall reimburse Orphan
Medical for its reasonable, documented out-of-pocket costs for such inspection and audit. 
  

 16 

 ARTICLE V 
 REGULATORY COMPLIANCE; PRODUCT MANUFACTURE 
  
 5.1 Regulatory Reporting. Celltech shall timely file all reports relating to the Product required by the Regulatory Authorities in each country in the Territory and shall deliver a copy of each such report in
hardcopy and on diskette, if available, to Orphan Medical within thirty (30) calendar days of making such report in accordance with laws in the Territory regarding transfer of data and confidentiality of patient information. 
  
 5.2 Product Recalls. (a) Each party shall promptly notify the other
party in the event of any recall, market withdrawal or correction of Product ordered by any Regulatory Authority, whether in the Territory, the United States, or anywhere in the world. The parties shall cooperate in good faith to handle and dispose
of a recall, market withdrawal or correction in the Territory. 
  
 (b) Subject to Section 5.2(c) below, in the event of a recall, market withdrawal or correction (i) by reason of the failure of all or part of the Product supplied by Orphan Medical to meet the Product Specifications, any requirement of the
FDA or any Marketing Authorization or other requirement of applicable law that is not the result of any action or omission of Celltech or its Subdistributors or Sublicensees as described in paragraph (c) below or (ii) because Product that meets the
Product Specifications, by whomsoever manufactured, is inherently defective, unsafe, dangerous or may harm users of the Product, Orphan Medical shall bear the costs of such recall, market withdrawal or correction (including without limitation
Celltech’s reasonable attorney’s fees). 
  
 (c) In the
event of a recall, market withdrawal or correction by reason of the failure of Celltech to have obtained or properly maintained or complied with a Marketing Authorization or as a result of Celltech’s (or its Subdistributors’,
Sublicensees’ or Third Party manufacturers’) breach of any of their obligations under this Agreement (including without limitation Section 3.7), or the willful misconduct or negligent acts or omissions of Celltech (or its Subdistributors,
Sublicensees’ or Third Party manufacturers’), Celltech shall bear all costs of such recall, market withdrawal, or correction (including without limitation Orphan Medical’s reasonable attorneys’ fees). 
  
 5.3 Adverse Event Notifications and Reporting. The exchange of Adverse
Event reports relating to the Product between the parties shall be made according to the procedures in Appendix D. 
  
 5.4 Correspondence/Complaints. (a) Celltech shall promptly provide Orphan Medical with copies of any material regulatory correspondence with
respect to the Product in the Territory and all related documentation, information and other materials received or prepared by Celltech, including, but not limited to, copies of the proposed applications for Marketing Authorization prepared by or on
behalf of Celltech for Registration of the Products in the Territory and any subsequent amendments, supplements, or annual updates thereto. 
  
 (b) Celltech agrees to inform Orphan Medical in writing of all significant complaints regarding the Product that relate to Product Specifications within
fifteen (15) business days after Celltech’s receipt thereof in all countries of the Territory. Celltech shall also 
  

 17 

 provide written quarterly reports of all complaints regarding the Product, regardless of significance, in English, as
well as the actions taken by Celltech to address all such complaints. Such reports shall be delivered to Orphan Medical within thirty (30) days after the end of each calendar quarter during the Term. 
  
 5.5 Translations. Celltech shall provide Orphan Medical English
translations of any material regulatory correspondence received in a language other than the English language relating to a Serious Adverse Event (as defined in Appendix D). Furthermore, Celltech shall provide to Orphan Medical copies of
translations of any other regulatory correspondence and reports delivered pursuant to Sections 5.1, 5.3 or 5.4 to the extent Celltech has otherwise translated such correspondence and reports for its own purposes. 
  
 5.6 Manufacture; Quality. Subject to Article VII, Orphan Medical
agrees to manufacture Celltech’s requirements for Product as necessary to satisfy Celltech’s forecasts and purchase orders submitted by Celltech pursuant to this Agreement. Products delivered to Celltech pursuant to this Agreement shall be
manufactured in accordance with the Quality Agreement negotiated and finalized between Orphan Medical and Celltech prior to Marketing Authorization approval in any country in the Territory, such agreement to be substantially in the form attached
hereto as Appendix E. Such Quality Agreement shall be agreed upon by the parties no later than twelve (12) months after the Effective Date. The Quality Agreement shall include the obligations and pharmaceutical responsibilities of Orphan
Medical, Orphan Medical’s sub-contractors and Celltech relating to the quality assurance requirements for the manufacture and supply of the Product, all in accordance with cGMP and applicable regulatory requirements. 
  
 5.7 Product Specifications. Product supplied to Celltech by Orphan
Medical shall meet the Product Specifications that are approved by the Regulatory Authorities in the Territory. Should the approved Product Specifications differ from the specifications contained in Orphan Medical’s NDA which are set forth on
Appendix C, the Product Specifications approved by the Regulatory Authorities shall control. 
  
 5.8 Manufacturing Audits by Celltech. Upon sixty (60) days prior written notice for cause, or with one hundred eighty (180) days written notice for
an annual audit, Celltech or a representative thereof shall have the right, if within the power of Orphan Medical to grant such right, to participate in the conduct of compliance or other inspections, audits and/or investigations of the operations
and facilities where the Product and the raw materials and components used to manufacture, package, inspect, test, store and supply the Product, including, without limitation, the API and the Components, are manufactured, packaged, inspected, tested
and stored. Such inspections, audits and/or investigations shall take place during normal business hours at the relevant manufacturing site(s) in the presence of Celltech and Orphan Medical’s representatives and Celltech shall abide by any
confidentiality requirements or security procedures of Orphan Medical’s suppliers. Orphan Medical shall facilitate and lead the audit, and it shall be Orphan Medical’s responsibility to discuss any audit findings with its sub-contractors
and suppliers. Celltech and Orphan Medical along with any other licensing partner will agree upon a final single audit report that will be sent to the vendor by Orphan Medical. In the event of any disagreement among the parties relating to the audit
report, Orphan Medical shall be the deciding entity and will finalize the audit report. Orphan Medical shall require its 
  

 18 

 sub-contractors and suppliers to take all reasonably necessary corrective actions identified by Celltech as necessary to
comply with cGMP requirements and Registrations in the Territory. In the case where a vendor will not allow Celltech to accompany Orphan Medical during such audit, Orphan Medical will either audit on behalf of Celltech, or will jointly, with
Celltech engage an independent third party to audit the supplier on behalf of both parties. Orphan Medical is generally allowed one audit each year of each vendor. If additional costs are imposed due to accompaniment of Celltech with Orphan Medical
during such audits, Celltech shall bear the burden of any additional costs. 
  
 ARTICLE VI 
 MARKETING EFFORTS 
  
 6.1 Marketing Efforts. Celltech shall have, directly or through its Subdistributors or Sublicensees, the following
obligations with respect to the marketing and distribution of the Product in the Territory: 
  
 (a) To use its Commercially Reasonable Efforts to promote, market, sell and distribute the Product in the countries in the Territory where Registrations are in good standing; provided, however, that
Celltech shall not be required to market the Product in any country in the Territory where pricing is regulated and the approved end user price is less than * of the Weighted Average List Price; 
  
 (b) To promptly respond to all inquiries or complaints from purchasers of the
Product; 
  
 (c) To maintain adequate and qualified staff to
enable it to fully perform its obligations hereunder; 
  
 (d) To
provide adequate and appropriate training to its staff concerning the Product; and 
  
 (e) To conduct its business in a professional manner. 
  
 6.2 Approved Product Claims. Celltech shall not make and shall cause its Subdistributors and Sublicensees to not make claims to any Third Party concerning the Product except as contained in or permitted by the
relevant Marketing Authorization or as approved in the Territory by the appropriate Regulatory Authority. 
  
 6.3 Development of Marketing Strategy. Celltech agrees to cooperate in the development of a consistent message strategy to promote the Product in
an effort to protect and strengthen branding. The global positioning of the Product for the U.S. and the Territory should be discussed before Celltech launches the Product in a country in the Territory and at least once per year (or more frequently
if reasonably requested by Orphan Medical) to ensure a message which is consistent with the local Marketing Authorizations and local treatment guidelines in such country, and, where possible, consistent with the international message. Celltech and
Orphan Medical agree to work in good faith to develop such a strategy. 
  

 19 

 6.4 Marketing Materials. Celltech agrees to provide Orphan Medical with copies of all marketing
and promotional materials within thirty (30) days of first use. Celltech shall be solely responsible for the text, graphics, and compliance of such materials with the laws and regulations of the Territory, but may rely (without further
investigation) on all Product information provided by Orphan Medical, except that Celltech may not rely on such information to the extent Celltech knows or reasonably should know that such information is inaccurate. 
  
 6.5 Sales and Technical Literature Developed by Orphan Medical. From
time to time during the Term Orphan Medical shall provide to Celltech reasonable quantities of such training, sales and technical literature and materials relating to the Product as Orphan Medical may have prepared, including, without limitation,
the materials set forth on Appendix H hereto, and shall make available copies of promotional artwork it may have. The cost of printing quantities or customizing materials shall be borne by Celltech. Orphan Medical shall provide the same to
Celltech in electronic format. Orphan Medical shall also provide Celltech with copies of all post-marketing studies and updates to its regulatory filings that it provides to the FDA. Celltech shall use such materials solely as provided under this
Agreement. Orphan Medical retains all right, title and interest in and to such materials subject, however, to the terms of this Agreement. 
  
 6.6 Marketing Reports. (a) At least one hundred eighty (180) days prior to the anticipated date of the First Commercial Sale, Celltech shall
provide Orphan Medical with sales and marketing plans for the Major European Countries for the balance of the Contract Year in which such First Commercial Sale occurs; provided, however, that in respect of Italy, Celltech shall deliver
a proposal to appoint a sub-licensee within one hundred eighty (180) days prior to the anticipated date of the First Commercial Sale, and shall provide Orphan Medical with a sales and marketing plan for Italy as soon as practicable after executing
an agreement with a sub-licensee relating to distribution of the Product in Italy. 
  
 (b) By 31 January of each Contract Year following the year in which the First Commercial Sale occurs, Celltech shall provide Orphan Medical with a written report summarizing its sales and marketing activities in the
Major European Countries for the immediately preceding year, and sales and marketing plans in the Major European Countries for the current Contract Year. Simultaneously with delivery of each marketing report described in this Section 6.6(b),
Celltech shall deliver reports as to the sales and marketing activities in the Minor European Countries (for the same periods as provided for the Major European Countries), provided that such reports need only outline the most important aspects and
plans of the sales and marketing in such Minor European Countries. Each report shall include the potential market for the Product in all countries of the Territory where Registration has been achieved and is anticipated during the Contract Year in
question, and other information that Celltech deems helpful to determine the market for Product and the proper marketing methods for the same. 
  
 6.7 Cooperation. Orphan Medical and Celltech agree to maintain open communications relating to the ongoing performance of this Agreement to ensure
joint understanding of current or new issues, data, and information. Orphan Medical shall answer reasonable technical or marketing questions Celltech may submit to Orphan Medical. Celltech acknowledges that Orphan Medical does not have international
marketing and regulatory staff for preparation of regulatory submissions and marketing plans. Orphan Medical and Celltech agree to provide each other copies of market research study protocols and subsequent results therefrom, which studies are
designed to generate qualitative and/or quantitative data pertaining to the Product, subject to any Third Party rights therein. 
  

 20 

 6.8 Named Patient Basis Sales. (a) Orphan Medical has contracted with * to distribute the Product
on a Named Patient Basis until the Product receives Marketing Authorization within the Territory. On or prior to the Effective Date, Orphan Medical shall provide to Celltech marketing and sales information to which Orphan Medical has rights under
the * agreement that has been collected by * . 
  
 (b)
Promptly after the Effective Date, the Steering Committee shall consider whether Orphan Medical should terminate Orphan Medical’s contract with * with respect to the Territory and cause * to discontinue sales of the Product within the
Territory, in which event Celltech would then be granted the right, subject to any necessary regulatory approvals, to distribute the Product on a Named Patient Basis in the Territory. 
  
 (c) Upon determination by the Steering Committee to proceed according to the arrangement described in Section 6.8(b) above,
the parties shall in good faith negotiate and establish the terms and conditions which shall apply to such arrangement, including, the price at which the Product will be sold. If * continues to distribute the Product on a Named Patient Basis, then
the parties shall in good faith negotiate and establish a royalty amount to be paid to Celltech on the revenues received by Orphan Medical from * on Named Patient Basis Product sales. 
  
 ARTICLE VII 
 PURCHASE AND DELIVERY OF PRODUCT 
  
 7.1 Forecasts. Celltech will provide Orphan Medical with rolling five (5) calendar quarter forecasts (“Commercial Forecasts”) of its anticipated requirements of Product to assist Orphan Medical
to adequately plan for and meet Celltech’s requirements for each country in the Territory. No later than one hundred twenty (120) days prior to the anticipated date of the First Commercial Sale, Celltech shall provide Orphan Medical with the
initial Commercial Forecast which shall cover the five (5) calendar quarters commencing with and including the calendar quarter in which the First Commercial Sale is expected to occur. Each Commercial Forecast after the first (i) shall cover the
five (5) calendar quarters commencing with the second calendar quarter of the preceding Commercial Forecast (ii) shall be delivered to Orphan Medical at least one hundred twenty (120) days prior to the first day of such five (5) calendar quarter
period and (iii) without Orphan Medical’s written consent may not forecast an aggregate quantity of Products that is more than three (3) times the aggregate quarterly forecast in the preceding Commercial Forecast. The quantities of Product for
the first calendar quarter of each Commercial Forecast shall be firm and Celltech shall be obligated to submit purchase orders in respect thereof. The quantities of Product for the remaining four (4) calendar quarters in each Commercial Forecast
shall be non-binding estimates based on Celltech’s reasonable business judgment. Celltech’s non-binding estimate for the first Contract Year in which the First Commercial Sale is expected to occur is provided in Appendix F hereto.

  

 21 

 7.2 Pricing. Subject to Sections 2.1(b) and 2.1(d) hereto, during the Term of this Agreement,
Celltech shall purchase from Orphan Medical all of its requirements of the Product in the Territory for the Transfer Price, plus any applicable customs duties or VAT. 
  
 7.3 Consignment of Product. 
  

(a) General. Within a reasonable period in advance of the anticipated date of the First Commercial Sale, to the extent importation is then
permitted under applicable law, Orphan Medical shall transfer to Celltech’s specified facility in England at least * of the Product (such Product, together with subsequent inventory of the Product to be held by Celltech as baillee pursuant to
the terms of this Section 7.3, shall be “Consignment Inventory”). Orphan Medical shall thereafter transfer to Celltech such quantities of the Product as the parties, with input from the Steering Committee, may subsequently agree in
order that the amount of Consignment Inventory plus the amount of finished goods inventory maintained by Celltech shall equal approximately the next six (6) months anticipated demand for the Product in the Territory; provided, that,
Orphan Medical shall in no event be required to transfer, and Celltech shall in no event be required to hold Consignment Inventory of more than one and one-half full lot quantities * without its prior written consent. Celltech shall hold the
Consignment Inventory as baillee for and on behalf of Orphan Medical. Celltech hereby acknowledges and agrees that Celltech’s holding the Consignment Inventory in its premises pursuant to the terms of this Section 7.3 shall constitute a
gratuitous bailment and not a bailment for valuable consideration governed by the U.K. Supply of Goods and Services Act 1982. The Product in the Consignment Inventory will at all times remain under the control of Celltech and be held for and on
behalf of Orphan Medical by Celltech as baillee until such time as the Product is removed from the Consignment Inventory by Celltech in fulfillment of a purchase order placed by Celltech in accordance with Section 7.4 hereof or repossessed by Orphan
Medical or returned by Celltech in accordance with Section 7.3(e)(iii) hereof. 
  
 (b) Prices and Payment. 
  
 (i) Celltech may remove Product from Consignment Inventory from time to time on a first-expired-first-out basis (subject, however, to Section 7.9) once per month upon submission of a purchase order pursuant to Section
7.4. Whenever an item of Consignment Inventory is removed from the Consignment Inventory, Celltech shall inform Orphan Medical in writing specifying the quantity removed, the batch/lot number of each bottle of the Product removed and the expiration
date thereof. Orphan Medical shall thereupon forward an invoice for such removed items of the Consignment Inventory, dated as of the date of removal. Title to, ownership and risk of loss of each such item shall be deemed to pass to Celltech as from
the moment said item is physically removed from the Consignment Inventory. The Transfer Price for such item, including duties and VAT, if any, shall become due and payable by Celltech by the last day of the first full calendar month after the date
of removal in accordance with provisions of Section 7.7 hereof. 
  
 (ii) Celltech agrees to act as the fiscal representative of Orphan Medical for purposes of customs, duties and VAT, and Celltech shall be solely responsible for payment of all such duties and taxes to the appropriate
U.K. authorities when due. 
  

 22 

 (iii) Celltech shall pay (or reimburse Orphan Medical for) all freight charges, insurance
in transit, taxes (including import VAT) and import duties incurred in connection with the transfer of the Consignment Inventory from Orphan Medical’s designated supplier in the U.S. to Celltech’s facilities. 
  
 (c) Storage and Risk. 
  
 (i) Celltech will at all times store the Consignment
Inventory in premises which have been certified by the Medicines Healthcare Regulatory Authority and any other relevant Regulatory Authority as suitable for U.K. Schedule 4, Part 1 controlled substances and as otherwise provided in Section 7.11.

  
 (ii) In the event that any item of
Consignment Inventory is lost or damaged through no fault of Orphan Medical, Celltech shall indemnify Orphan Medical in respect of any such loss or damage by paying the Transfer Price for each item lost or damaged, plus duties and VAT, if any.

  
 (iii) Celltech will store the Consignment
Inventory separately from any goods that belong to Celltech or any Third Party and shall clearly mark and identify the Consignment Inventory as being held on behalf of Orphan Medical. 
  
 (iv) Celltech shall at its expense at all times maintain adequate insurance covering any risk of loss or
damage to the Consignment Inventory for its full Transfer Price and naming Orphan Medical as sole loss payee and shall forward a copy of evidence of such insurance and any amendment thereto to Orphan Medical. 
  
 (d) Records. Celltech shall maintain full and accurate records showing
the quantity of Consignment Inventory, the lot identification, expiration dates and such other information as is necessary to enable a Third Party to identify that each item of Consignment Inventory forms part of the Consignment Inventory and is
being held on behalf of Orphan Medical under the supervision and control of Celltech. 
  
 (e) Termination. 
  
 (i) The bailment created pursuant to this Section 7.3 shall terminate with immediate effect on the last day of the Term of this Agreement. 
  
 (ii) Orphan Medical may also terminate the bailment created pursuant to this Section 7.3 with immediate
effect, by giving written notice to that effect to Celltech, if any liquidation, receivership, administration or other insolvency procedure is commenced or threatened with respect to Celltech or any entity which has control over Celltech. Orphan
Medical may also terminate this Agreement if any action is taken or threatened which might jeopardise Orphan Medical’s rights in the Consignment Inventory. 
  

 23 

 (iii) Termination of the bailment for whatever reason shall be without prejudice to the
accrued rights of a party. Celltech shall not thereafter use any items of Consignment Inventory or remove any items from Consignment Inventory without the specific prior written consent of Orphan Medical. Upon such termination, Celltech’s
obligations under this Section 7.3 shall continue in full force and effect until such time as Orphan Medical has repossessed the Consignment Inventory as provided in paragraph (f) or Celltech has returned the Consignment Inventory by shipment to
Orphan Medical Ex Works (Incoterms 2000) at the Celltech facility at which it is kept. 
  
 (f) Return of Consignment Inventory. Orphan Medical shall be entitled to repossess the Consignment Inventory immediately upon termination of the bailment or prior to termination if Orphan Medical determines in
its sole discretion that repossession is necessary for any reason. Celltech, or any person managing Celltech’s activities, shall give any duly authorised representative or agent of Orphan Medical such access to Celltech’s premises as are
required for purposes of repossessing the Consignment Inventory. 
  
 (g) Periodic Review. At any time and from time to time, either party may request the other party to discuss and consider in good faith changes in, or termination of, the arrangements for Consignment Inventory, whereupon the parties
shall be mutually obligated to negotiate in good faith as to such matters. 
  
 7.4 Purchase Orders. 
  
 (a) Content. All purchase orders placed by Celltech shall be in writing and shall state the quantity of Product, the delivery date, shipping information (except when the Product is to be drawn from Consignment Inventory pursuant to
Section 7.3) and such other similar information as may be reasonably requested by Orphan Medical. 
  
 (b) Lead Time. Unless otherwise agreed by Orphan Medical, all purchase orders must be delivered to Orphan Medical at least one hundred twenty (120)
days in advance of the requested delivery date(s) (except when the Product is to be drawn from Consignment Inventory pursuant to Section 7.3). 
  
 (c) Number of Orders. Celltech may submit only one purchase order per quarter for Product to be filled by Orphan Medical from other than
Consignment Inventory and may submit one purchase order per month for Product to be drawn from Consignment Inventory. 
  
 (d) Maximum Quantities. Orphan Medical may in its sole discretion reject purchase orders that specify a quantity of Product in respect of a
particular calendar quarter in excess of (A) * of the firm Commercial Forecast for such quarter if such firm Commercial Forecast is more than * greater than the most recent non-binding Commercial Forecast for such quarter and (B) * of the firm
Commercial Forecast if such firm Commercial Forecast is less than * greater than the most recent non-binding Commercial Forecast for such quarter; provided, however, that the maximum quantities that Orphan Medical shall be required to
deliver in a 
  

 24 

 particular calendar quarter determined in accordance with clauses (A) and (B) above shall be reduced by the quantity of
Product Orphan Medical shall have delivered in the preceding calendar quarter pursuant to paragraph (e) below in excess of the maximum quantities it was required to provide in such preceding calendar quarter as determined pursuant to this paragraph
(d). 
  
 (e) Miscellaneous. Orphan Medical shall use its
Commercially Reasonable Efforts to fill purchase orders that exceed the quantity limits provided in paragraph (d) above or that are delivered to Orphan Medical less than one hundred twenty (120) days in advance of the requested delivery date(s) as
required by paragraph (b) above in respect of purchase orders to be filled by Orphan Medical from other than Consignment Inventory. No accepted order may be modified or canceled by either party except as agreed in writing by the parties.
Celltech’s orders (including mutually agreed change orders) shall be subject to the provisions of this Agreement, and any terms or conditions contained therein that conflict with the terms of this Agreement shall be deemed excluded. 

 
 7.5 Delivery From Other Than Consignment Inventory. Where purchase
orders are to be filled by Orphan Medical from other than Consignment Inventory, Orphan Medical shall deliver the Products no later than five (5) business days after the date(s) indicated in the applicable purchase order and no earlier than five (5)
business days prior to such specified date(s). Orphan Medical shall provide prompt written notice to Celltech in the event of any anticipated delays in the scheduled delivery date and shall cooperate with Celltech to reschedule delivery at the
earliest possible date so as to minimize the impact on Celltech, provided, however, the foregoing shall in no way modify or mitigate Orphan Medical’s obligation to supply Product properly ordered in accordance with this Agreement
or Celltech’s rights and remedies under this Agreement in respect of any failure to timely supply, including Celltech’s right to assert its remedies in respect of a breach hereof and Celltech’s rights to appoint a Third Party
manufacturer in accordance with Section 2.1(b) or to terminate this Agreement in accordance with Section 14.2(b). Orphan Medical shall send Celltech on the date of shipment an invoice and shipping notice, in a format to be agreed upon by the
parties. All Products shall be properly packaged and shipped in accordance with the Product Specifications and instructions included in the applicable purchase order. Unless otherwise agreed in writing by Orphan Medical, all deliveries of the
Product from other than Consignment Inventory shall be made Ex Works (Incoterms 2000) Orphan Medical’s designated supplier in the U.S. 
  
 7.6 Transfer Price Variations. At least one hundred twenty (120) days prior to the end of the 2004 Contract Year and each Contract Year thereafter,
Orphan Medical shall notify Celltech of the Transfer Price for the Product for the next Contract Year. Orphan Medical shall reserve the right to increase transfer pricing on an annual basis for any increases in the costs identified in Appendix
G imposed on Orphan Medical by its suppliers. Orphan Medical shall reduce transfer pricing on an annual basis for any decreases in the costs referenced in the preceding sentence and for any other reductions in the components of Orphan
Medical’s standard manufacturing costs as listed on Appendix G (including any reductions that may result from decreases in the required fill volume resulting from improvements in the PIBA). Each such notice shall include all necessary
documentation reasonably required for Celltech to verify the adjusted Transfer Price; provided, however that notwithstanding Orphan Medical’s delivery of such documentation, Celltech shall be permitted to conduct inspections and
audits during 
  

 25 

 reasonable business hours, to the extent necessary to verify the Transfer Price and adjustments thereto. Such inspections
and audits shall be conducted at the request (not to be made more than once per Contract Year) and expense of Celltech by an independent Certified Public Accountant appointed by Celltech. Such Certified Public Accountant shall undertake a
confidentiality obligation to Orphan Medical permitting it to disclose only to Celltech the amount of the Transfer Price and adjustments and the information required to verify such Transfer Price and adjustments, and no other information.

  
 7.7 Payment Terms. 
  
 (a) General. Unless otherwise agreed by Orphan Medical in writing,
payments for the Product shall be paid net on the last day of the first full calendar month following the date of the invoice therefor, provided that no invoice shall be dated prior to the date of actual shipment of the Product covered by the
invoice or removal of the Product from Consignment Inventory. All payments shall be made in United States Dollars by wire transfer to a U.S. bank designated by Orphan Medical at least five (5) days prior to the date of payment. Any overdue payment
from Celltech to Orphan Medical under this Agreement shall accrue interest at the rate of 3/4% per month or the highest rate allowed by law, whichever is less. Orphan Medical shall have the right to recover its reasonable collection costs and
expenses (including attorneys’ fees) for late payments. Notwithstanding the above, in the event Celltech disputes the amount, or any portion thereof, of any invoice submitted to it by Orphan Medical, Celltech shall promptly notify Orphan
Medical of the amount and nature of the disagreement. Before relying on the provisions of Section 15.2 hereof, the parties first shall promptly attempt to resolve such disagreement in good faith in a manner provided in Section 7.7(b) and Celltech
shall make payments with respect to disputed invoices as provided in such Section. 
  
 (b) Order and Invoice Non-Conformance. 
  
 (i) In the event Celltech disputes whether Product supplied by Orphan Medical conforms to an order placed for such Product pursuant to Section 7.4 with respect to quantity where purchase orders are to be filled by
Orphan Medical from other than Consignment Inventory, Celltech shall provide notice to Orphan Medical in accordance with the provisions relating to apparent non-conformities of Product set forth in Section 7.12. In the case of any such
non-conformity which results from delivery of less Product than ordered, Orphan Medical shall supply additional Product promptly. In such case, Celltech shall pay for the quantity actually received in accordance with the provisions of Section
7.7(a). In the case of any such non-conformity which results from delivery of more Product than ordered, Celltech may elect to (A) add such excess Product to Consignment Inventory or, if Orphan Medical shall so specify, return to Orphan Medical, at
Orphan Medical’s expense, any Product in excess of the quantity of Product ordered in accordance with the procedures for return set forth in Section 7.12, or (B) accept any Product in excess of the quantity ordered as against future orders of
Product. In such latter case, Celltech shall pay for the quantity actually received and accepted in accordance with the provisions of Section 7.7(a) unless otherwise agreed. 
  

 26 

 (ii) In the event that Celltech disputes any invoice due to the price at which any
quantity of Product is invoiced as a result of the parties being unable to reach agreement with respect to the calculation of the Transfer Price, Celltech shall be obligated to pay the undisputed amount of such invoice in full in accordance with the
provisions of Section 7.7(a) pending resolution of the dispute pursuant to Section 15.2. 
  
 (iii) In the event that Celltech disputes any invoice due to non-conformance of the Product supplied by Orphan Medical with the Product
Specifications, such dispute shall be resolved in accordance with Sections 7.12 and 7.13 of this Agreement. Pending resolution of such dispute, Celltech shall not be obligated to pay the amount of such invoice that relates to Product alleged to be
non-conforming. Upon resolution of any such dispute in favor of Orphan Medical, Celltech shall pay the unpaid balance of such invoice within ten (10) days of such resolution. 
  
 7.8 Short Supply Allocation. If Orphan Medical is unable to supply all of Celltech’s orders for Product
hereunder in a timely manner, Orphan Medical shall equitably allocate its available sources and supplies among Celltech, Orphan Medical and Orphan Medical’s other partners (distributors, licensees, agents, etc.) and internal needs, taking into
consideration the respective requirements of each of the parties during a reasonable time period prior to allocation and their requirements during the allocation period, provided, however, the foregoing shall in no way modify or
mitigate Orphan Medical’s obligation to supply Product properly ordered in accordance with this Agreement or Celltech’s rights and remedies under this Agreement in respect of any failure to timely supply, including in respect of a breach
hereof and Celltech’s rights to appoint a Third Party manufacturer in accordance with Section 2.1(b) or to terminate this Agreement in accordance with Section 14.2(b). 
  
 7.9 Product Expiration. (a) All Product supplied by Orphan Medical from other than Consignment Inventory shall have a
minimum expiration dating of thirty-six (36) months at the time of its delivery Ex Work’s Orphan Medical’s designated supplier pursuant to Section 7.5. 
  
 (b) The Product delivered in the initial transfer of Consignment Inventory from Orphan Medical to Celltech made in
accordance with the first sentence of Section 7.3(a) shall have minimum expiration dating of forty-two (42) months at the time it is delivered to Celltech’s facility in England. Thereafter, all Product delivered by Orphan Medical as Consignment
Inventory pursuant to Section 7.3 shall have minimum expiration dating of thirty-six (36) months at the time it is delivered to Celltech’s facility in England. Celltech shall not be required to draw out of Consignment Inventory any Product with
expiration dating of less than twenty-four (24) months on the date that it is drawn out of Consignment Inventory; provided, however, that if the Consignment Inventory shall at any time contain Product with less than 24-month’s
expiration dating, Celltech shall use Commercially Reasonable Efforts to sell such Consignment Inventory, and provided, further, however, that if Celltech shall not be able to sell such short-dated Consignment Inventory,
Celltech shall, at Orphan Medical’s direction, either return such Product to Orphan Medical Ex Work’s Celltech’s facility in England or destroy the Product and provide the certification described in Section 7.12, and in either such
event Orphan Medical shall reimburse Celltech for all amounts paid by Celltech pursuant to Sections 7.3(b)(ii) and (iii). 
  

 27 

 (c) In the event the applicable Regulatory Authority grants an expiration date of less than thirty-six
(36) months, Orphan Medical and Celltech shall negotiate in good faith a reasonable minimum expiration, taking into account the differing expiration dates set forth herein for Product which is and Product which is not drawn out of Consignment
Inventory. 
  
 (d) Celltech shall not sell any Product beyond its
stated expiration date. 
  
 7.10 Certificate of Analysis.
With each delivery of the Product into Consignment Inventory pursuant to Section 7.3 or to Celltech from other than Consignment Inventory, Orphan Medical shall provide to Celltech (i) a Certificate of Analysis and Certificate of Conformity
confirming that the Product has been manufactured in accordance with cGMP and the Product Specifications, (ii) a copy of all batch documentation from the Product manufacturer for the first three (3) batches of Product delivered to Celltech and (iii)
a copy of the annual stability test report, provided that the provision of the certificates and other documents listed in (i) - (iii) above shall not release Celltech from any of its obligations hereunder, including, without
limitation, its obligation to conduct all necessary release testing to ensure that the Products distributed in the Territory comply with all applicable regulatory requirements in the Territory. 
  
 7.11 Storage. Celltech shall at its own expense maintain adequate and
suitable storage facilities for the storage of Consignment Inventory and Product delivered to Celltech from other than Consignment Inventory, in each case in accordance with cGMP, the Marketing Authorizations, and all applicable laws and
regulations. Orphan Medical or its representative shall have the right no more than twice per calendar year to inspect, during normal business hours, such storage facilities upon sixty (60) days prior written notice. 
  
 7.12 Rejection of Shipments For Product Non-Conformance. If Celltech
rejects a shipment from other than Consignment Inventory on the determination that such shipment of Product fails to conform to the purchase order therefor or a shipment of Consignment Inventory or Product delivered to Celltech from other than
Consignment Inventory or drawn by Celltech out of Consignment Inventory on the grounds that it fails to conform to the Product Specifications, Celltech shall give written notice of such rejection to Orphan Medical within fifteen (15) days after
receipt thereof, in the case of apparent non-conformance, and sixty (60) days of the receipt of definitive test results obtained pursuant to Section 7.13 in the case of non-conformance established by such tests. Such notice of rejection shall
specify the manner in which the Product fails to conform to the relevant purchase order, or otherwise fails to conform to the Product Specifications. If Celltech fails to provide Orphan Medical such notice in respect of Product delivered to Celltech
pursuant to a purchase order, whether drawn from Consignment Inventory or otherwise, within fifteen (15) or sixty (60) days, as the case may be, of the date of delivery, the Product shall be deemed accepted by Celltech; provided,
however, that such deemed acceptance shall not (i) impair Celltech’s right to reject shipment or recover damages in respect of any non-conformance that is not apparent and cannot be determined by such tests or (ii) reduce, diminish or
alter Celltech’s rights to indemnification as specified in Article IX hereof or to terminate this Agreement in accordance with Section 14.2(b). If Celltech expects to make a claim against Orphan Medical in accordance with this Section 7.12,
Celltech shall not dispose or 
  

 28 

 allow the disposal of the Product in question without the express written authorization and instructions of Orphan
Medical. Any such instructions from Orphan Medical, or Celltech’s compliance therewith, shall not relieve Celltech of its obligation to dispose of any Product in accordance with all applicable laws and regulations in the relevant country in the
Territory. Celltech shall not return any rejected Product to Orphan Medical without a Return Material Authorization (“RMA”) from Orphan Medical. Orphan Medical shall promptly issue a RMA for any reasonably rejected Product,
provided, however, appropriate samples may be retained by Celltech as evidence of the basis for such rejection by Celltech. Proof of destruction or disposal shall be certified in writing to Orphan Medical by an officer of Celltech.
Within thirty (30) days of receipt of a statement detailing and documenting all of Celltech’s costs and expenses associated with Orphan Medical’s delivery of non-conforming Products, including without limitation, any payments made or other
Indemnification Amounts arising out of Claims and the return, destruction or disposal of such Product pursuant to this Section 7.12, Orphan Medical shall reimburse Celltech for all such amounts. Any disputes between the parties relating to such
reimbursement amounts shall be resolved in accordance with the procedures set forth in Section 15.2 
  
 7.13 Testing of Product Upon Receipt. Celltech shall, as soon as practical after receipt of Product into Consignment Inventory or from other than
Consignment Inventory, examine the Product for any apparent non-conformance and carry out or have carried out, routine laboratory testing and other chemical analysis of the Product as required by the relevant Marketing Authorizations and/or
Regulatory Authority(ies). Celltech shall promptly notify Orphan Medical if such examination or testing establishes the basis to reject the Product for non-conformance. Any such notice shall identify the specific claims of non-conformance and
include copies of relevant test results or other materials indicating such non-conformance. Upon receipt of a notification of non-conformance, Orphan Medical and Celltech shall compare test results obtained during release testing of the Product by
Orphan Medical to the results Celltech obtained during acceptance testing to evaluate the potential cause of discrepancy. If Orphan Medical confirms such non-conformity, it shall promptly so notify Celltech. If Orphan Medical does not confirm such
non-conformity, it shall promptly so notify Celltech, and the parties shall submit the disputed Product shipment for testing to an independent testing laboratory or other independent Third Party expert mutually acceptable to the parties.
Notwithstanding Section 15.2, the findings of the testing laboratory or Third Party expert shall be binding on the parties. The expenses of such testing shall be borne by Orphan Medical if the non-conformity is confirmed, and otherwise by Celltech.
Without limiting Celltech’s other remedies as herein provided, Orphan Medical shall promptly replace properly rejected Product. Celltech shall return such Product or, if requested by Orphan Medical, destroy the Product and provide the
certification described in Section 7.12. 
  
 ARTICLE VIII

 REPRESENTATIONS AND WARRANTIES 
  
 8.1 Orphan Medical Warranties. Orphan Medical represents and warrants to Celltech that: 
  
 (a) It is a corporation duly organized, validly existing and in good
standing under the laws of the state of Delaware, U.S.A. and has the corporate power to own its assets and properties and to carry on its business as now being and heretofore conducted. 
  

 29 

 (b) It has all requisite power and authority (corporate and otherwise) to enter into this Agreement and
it has duly authorized, by all necessary action, the execution and delivery hereof by the officer or individual whose name is signed on its behalf below. Orphan Medical’s execution and delivery of this Agreement does not and will not conflict
with or result in a breach of or a default under its organizational documents or any agreement, instrument, order, law or regulation applicable to it or by which it or the Product may be bound. This Agreement has been duly and validly executed and
delivered by Orphan Medical and constitutes Orphan Medical’s valid and legally binding obligation, enforceable against Orphan Medical in accordance with its terms, except as enforcement may be limited by laws of bankruptcy or insolvency or
other laws of general application relating to or affecting the enforcement of creditor’s rights and general equitable principles. 
  
 (c) At the time of its shipment to Celltech, each order of Product shall have been manufactured, stored and shipped in accordance with cGMP, the Product
Specifications and the Marketing Authorizations and other applicable laws and regulations, shall be in compliance with the Marketing Authorizations, and shall not be adulterated or misbranded within the meaning of the United States Food, Drug and
Cosmetics Act, as in effect at the time of shipment; 
  
 (d) At
the time of its shipment to Celltech, each order of the Product shall conform to the Product Specifications until the expiration of the shelf life approved by the Regulatory Authorities. 
  
 (e) Patent Rights, Trademarks and Other Intellectual Property Rights. 
  
 (i) Orphan Medical has good title and ownership or rights to
the Licensed Intellectual Property free and clear of all liens. To Orphan Medical’s actual knowledge, it has all intellectual property rights necessary for (A) the manufacture of the Product by Orphan Medical and the distribution, marketing,
promotion and sale by Celltech of the Product in the Territory in accordance with the terms of this Agreement and (B) the grant by Orphan Medical to Celltech of the rights granted under this Agreement. 
  
 (ii) Schedule 8.1(e)(ii) hereto contains a true and
complete list of all Patent Rights in the Territory and all Trademarks and all other intellectual property rights of Orphan Medical relating to the Product in the Territory, indicating for each whether it is registered or is the subject of a pending
application with any patent and/or trademark office with jurisdiction in the Territory, and all licenses and other contracts and similar rights relating thereto. 
  
 (iii) Except as set forth on Schedule 8.1(e)(iii), to Orphan Medical’s actual knowledge, the
Product as manufactured and delivered to Celltech by Orphan Medical for distribution in the Territory pursuant to this Agreement, and Celltech’s use of the Licensed Intellectual Property in the Territory as contemplated hereby, does not and
will not infringe or conflict with any intellectual property rights or trade secrets of any Person. 
  

 30 

 (f) Contracts; No Default. 
  
 (i) Except for those contracts described in Section 6.8 or set forth on Schedule 8.1(f)(i) and
Schedule 8.1(e)(ii) and except for this Agreement, as of the date hereof, there are no material contracts, agreements, understandings, arrangements or commitments, written or oral, including without limitation, manufacturing, supply, sales
agency, sales representative, distributor, dealer, license, supplier, wholesaler, or similar contracts or agreements (“Contracts”) of Orphan Medical relating to the Product in the Territory. 
  
 (ii) Except as set forth on Schedule 8.1(f)(ii),
Orphan Medical and, to Orphan Medical’s actual knowledge, each other party to Orphan Medical’s Contracts referenced in clause (i) above (other than Celltech) has performed in all material respects, and is now performing in all material
respects, its obligations under, and is not in material default (and would not by the mere lapse of time or the giving of notice or both be in default) under, or in material breach or violation of any of such Contracts; nor has Orphan Medical
received notice of any asserted claim of a default by any other party thereto under, or a breach or violation by such other party of any of such Contracts. 
  
 (g) Actions. 
  
 (i) Except as set forth on Schedule 8.1(g)(i), there are no Claims pending or, to Orphan Medical’s actual knowledge,
threatened against Orphan Medical before any Regulatory Authority that (A) question or challenge the validity of this Agreement or any action taken or proposed to be taken by Orphan Medical pursuant hereto or in connection with the transactions
contemplated hereby, or (B) relate to the Product or would if adversely determined, singly or in the aggregate, prohibit or materially impair Orphan Medical’s or Celltech’s ability to perform its obligations under this Agreement.

  
 (ii) There are no outstanding judgments,
orders, decrees, writs, awards, stipulations, or injunctions of any Regulatory Authority against or affecting the Product or Orphan Medical with respect to the Product or which would if adversely determined, singly or in the aggregate, prohibit or
materially impair Orphan Medical’s or Celltech’s ability to perform its obligations under this Agreement. 
  
 (h) Approvals. Except as contemplated by this Agreement or set forth on Schedule 8.1(h) or as shall already have been made, obtained or
given, no approval of any Regulatory Authority or other Person is required to be made, obtained or given by or with respect to Orphan Medical or the Product in connection with the execution or delivery by Orphan Medical of this Agreement, the
performance by it of its obligations hereunder or the consummation by it of the transactions contemplated hereby. 
  

 31 

 8.2 Disclaimer. EXCEPT AS SET FORTH IN THIS ARTICLE VIII, ORPHAN MEDICAL MAKES NO WARRANTIES,
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT WITH RESPECT TO THE PRODUCT OR CELLTECH’S SALE AND DISTRIBUTION THEREOF IN THE TERRITORY. The
warranties given by Orphan Medical are for the sole benefit of Celltech and Celltech shall not extend such warranties to any customer thereof or any Third Party. This provision does not affect the right of any patient to pursue legal remedy in the
event Orphan Medical provides Product that is adulterated or misbranded or if Product does not meet Product Specifications. Except as provided in Section 2.1, nothing in this Agreement shall be construed as, and Orphan Medical expressly disclaims,
any warranty or agreement to furnish any manufacturing information beyond that required to obtain Registrations for the Product in the Territory. Celltech agrees that as between Celltech and Orphan Medical, Celltech alone shall be liable, to the
exclusion of Orphan Medical, for the breach of any warranties given by Celltech, its Subdistributors or its Sublicensees to customers or others regarding the Product, provided, however, nothing herein shall reduce, diminish or alter
Celltech’s rights as herein provided including its right to assert claims against Orphan Medical in respect of the same facts that form or might form the basis of Claims against Celltech by its Subdistributors or Sublicensees and its or their
customers. 
  
 8.3 Celltech Warranties. Celltech represents
and warrants to Orphan Medical that: 
  
 (a) It is a corporation
duly organized, validly existing and in good standing under the laws of England and has the corporate power to own its assets and properties and to carry on its business as now being and heretofore conducted. 
  
 (b) It has all requisite power and authority (corporate and otherwise) to
enter into this Agreement and it has duly authorized, by all necessary action, the execution and delivery hereof by the officer or individual whose name is signed on its behalf below. Celltech’s execution and delivery of this Agreement does not
and will not conflict with or result in a breach of or a default under its organizational documents or any agreement, instrument, order, law or regulation applicable to it or by which it or the Product may be bound. This Agreement has been duly and
validly executed and delivered by Celltech and constitutes Celltech’s valid and legally binding obligation, enforceable against Celltech in accordance with its terms, except as enforcement may be limited by laws of bankruptcy or insolvency or
other laws of general application relating to or affecting the enforcement of creditor’s rights and general equitable principles. 
  
 (c) It shall and shall cause its Subdistributors, Sublicensees and Third Party manufacturers to manufacture (if applicable), store, package, label,
promote, market, sell and distribute the Product in compliance with this Agreement, the Registrations and all applicable laws and regulations in the Territory. 
  

(d) Celltech shall not, and shall cause its Subdistributors, Sublicensees and Third Party manufacturers to not knowingly, infringe any Third Party
patents, copyrights, trademarks, trade secrets or other Third Party intellectual property or proprietary rights in the performance of its obligations hereunder. 
  

 32 

 (e) Contracts; No Default. 
  
 (i) Except for those Contracts set forth on Schedule 8.1(e)(i) and except for this Agreement, as of
the date hereof, there are no material Contracts of Celltech relating to the Product in the Territory. 
  
 (ii) Except as set forth on Schedule 8.1(e)(ii), Celltech and, to Celltech’s actual knowledge, each other party to
Celltech’s Contracts referenced in clause (i) above (other than Orphan Medical) has performed in all material respects, and is now performing in all material respects, its obligations under, and is not in material default (and would not by the
mere lapse of time or the giving of notice or both be in default) under, or in material breach or violation of any of such Contracts; nor has Celltech received notice of any asserted claim of a default by any other party thereto under, or a breach
or violation by such other party of any of such Contracts. 
  
 (f)
Actions. 
  
 (i) Except as set forth on
Schedule 8.1(f)(i), there are no Claims pending or, to Celltech’s actual knowledge threatened against Celltech before any Regulatory Authority that (A) question or challenge the validity of this Agreement or any action taken or proposed
to be taken by Celltech pursuant hereto or thereto or in connection with the transactions contemplated hereby, or (B) would if adversely determined, singly or in the aggregate, prohibit or materially impair Orphan Medical’s or Celltech’s
ability to perform its obligations under this Agreement. 
  
 (ii) There are no outstanding judgments, orders, decrees, writs, awards, stipulations, injunctions of any Regulatory Authority against or affecting Celltech which would if adversely determined, singly or in the
aggregate, prohibit or materially impair Celltech’s ability to perform its obligations under this Agreement. 
  
 (g) Approvals. Except as contemplated by this Agreement or set forth on Schedule 8.2(g) or as shall already have been made, obtained or
given, no approval of any Regulatory Authority or other Person is required to be made, obtained or given by or with respect to Celltech or the Product in connection with the execution or delivery by Celltech of this Agreement, the performance by it
of its obligations hereunder or the consummation by it of the transactions contemplated hereby. 
  
 ARTICLE IX 
 INDEMNIFICATION 
  
 9.1 Indemnification by Orphan Medical. Subject to Section 9.2, Orphan Medical shall indemnify and hold harmless
Celltech and its directors, officers, employees and agents from and against all claims, disputes, actions, arbitrations, mediations, litigations, proceedings, suits and governmental investigations brought by a Third Party and any appeal therefrom
(the “Claims”) and all liabilities, damages, losses, costs and expenses (including reasonable 
  

 33 

 attorneys’ fees and expenses in respect of Claims and to enforce rights to indemnification as herein provided
(“Indemnification Amounts”)) arising out of (i) a breach by Orphan Medical of any representation, warranty or covenant provided in this Agreement, including, without limitation, the representations and warranties set forth in
Section 8.l, (ii) an allegation that bodily injury (including death) or tangible personal property damage was caused by, resulted from or arose out of the use of the Product for a Licensed Indication by whomsoever such Product was sold (including
Celltech, its Subdistributors and Sublicensees) and regardless of the legal theory on which such Claim is based, except, however, where such bodily injury and/or property damage is due to (a) a circumstance described in Section 9.2(i)
or 9.2(iii) hereof or (b) failure of a Third Party manufacturer appointed by Celltech pursuant to Section 2.1 to manufacture, store or ship the Product in accordance with cGMP, the Marketing Authorizations and other applicable laws and regulations
or due to the action or inaction of such Third Party manufacturer which causes the Product to be adulterated or misbranded within the meaning of the United States Food, Drug and Cosmetic Act, as in effect at the time of shipment; and (iii)
negligence, gross negligence or willful misconduct of or attributable to Orphan Medical, its sublicensees (other than Celltech, its Subdistributors, Sublicensees or Third Party manufacturers), contractors, manufacturers and its or their directors,
officers, agents, employees, consultants or clinical investigators in connection with the manufacture, storage or supply of API and/or the Product. 
  
 9.2 Indemnification by Celltech. Celltech agrees to indemnify, defend and hold harmless Orphan Medical and its directors, officers, employees and
agents from and against all Claims and Indemnification Amounts arising out of (i) a breach by Celltech of any representation, warranty or covenant provided in this Agreement, (ii) an allegation that bodily injury (including death) or tangible
personal property damage was caused by, resulted from or arose out of the Products sold by Celltech, its Subdistributors, Sublicensees or Third Party manufacturers that were used other than for a Licensed Indication, regardless of the legal theory
on which such Claim is based, except, however, where such bodily injury and/or property damage is due to a circumstance described in Sections 9.1(i) and 9.1(iii) hereof, (iii) negligence, gross negligence or willful misconduct of or
attributable to Celltech, its Subdistributors, Sublicenses or Third Party manufacturers and its or their directors, officers, agents, employees, consultants or clinical investigators in connection with the storage, packaging, labeling, promotion,
marketing, sale and distribution of the Product in the Territory; and (iv) any express or implied warranty, whether oral or written, including any implied warranty or the merchantability or fitness of the Product for a particular purpose asserted by
any customer of Celltech, its Subdistributors or Sublicensees, if such warranty was extended by or arising from any undertaking, action or inaction of Celltech, its Subdistributors or Sublicensees. 
  
 9.3 Procedure. A party seeking indemnification (an
“indemnified party”) shall give the other party (an “indemnifying party”) written notice of any Claim promptly upon becoming aware thereof. The indemnifying party shall have sole and exclusive control of the defense
of any Claim, including the choice and direction of legal counsel. The indemnified party shall have the right to participate in such defense through its own counsel, at its own expense. Neither party may settle or compromise any Claim for which
indemnification is being sought without the written consent of the other party, which may not be unreasonably withheld. 
  
 9.4 Insurance. Both parties shall maintain during the Term of this Agreement, and for a reasonable period thereafter, general liability insurance
(whether Third Party insurance or self- 
  

 34 

 insurance provided through a captive insurance subsidiary), which insurance shall include product liability coverage and
shall be in amounts and of a type customarily maintained by companies similarly situated. Such insurance shall provide at least * U.S. Dollars in coverage per occurrence. Each party shall use Commercially Reasonable Efforts to name the other party
as an additional insured on such party’s insurance policy(ies). On or prior to the Effective Date, each party shall deliver to the other evidence of its insurance. 
  
 ARTICLE X 
 INTELLECTUAL PROPERTY RIGHTS 
 PERFECTION AND USE 
  
 10.1 License Perfection. In the event that the execution and filing of any document is required in connection with
the license granted in Section 2.2 to Celltech for the Trademark or Patent Rights under the laws of any country in the Territory, Celltech shall promptly notify Orphan Medical, and Orphan Medical shall cause such document to be executed and filed,
and Celltech shall sign such document if necessary and otherwise cooperate in the filing thereof. 
  
 10.2 Quality Standards. All Products sold and marketed under the Trademark by Celltech or its Subdistributors or Sublicensees, including all
related advertising, promotional materials, and all other related uses of the Trademark shall comply with the reasonable trademark use standards adhered to by Orphan Medical in the manufacture, sale and promotion of the Product, which such standards
are set forth in Appendix I. In particular, and without limiting the generality of the foregoing, upon reasonable request by Orphan Medical, Celltech shall provide Orphan Medical with samples of Products bearing the Trademark, as well
as copies of all materials, including but not limited to brochures, professional literature, packaging and consumer instructions, which are created or intended for use by Celltech, its Subdistributors and/or Sublicensees in the advertising,
promotion, marketing or sale or other distribution of the Product in the Territory, for examination and testing to verify compliance with the trademark use standards set forth in Appendix I. Celltech shall also permit Orphan Medical,
not more than once per Contract Year and upon thirty (30) days prior written notice and at reasonable times during normal business hours, to examine stocks of the Product held by it or its Subdistributors or Sublicensees to verify compliance with
such standards. Orphan Medical shall notify Celltech in writing of any noncompliance herewith, and Celltech shall use Commercially Reasonable Efforts to correct the problem and bring such Products into compliance with applicable standards.

  
 10.3 Use of Trademark. Celltech shall and shall cause
its Subdistributors and Sublicensees to market the Product under the Trademark; provided, however that if the Trademark is unavailable or unusable in a particular country in the Territory, the parties shall mutually agree on a suitable
alternative. In addition, to the extent permitted by applicable law in each country in the Territory, all labeling for the Product shall bear a legend, identifying Orphan Medical as the manufacturer of the Product for Celltech. 
  
 10.4 Registration and Approvals. Attached hereto as Appendix B
is a list of the registrations and pending applications for registration for the Trademark and Patent Rights in the Territory. Orphan Medical shall file applications and maintain trademark registrations (including for the Trademark and any
alternative trademarks pursuant to Section 10.3) and patent 
  

 35 

 registrations (including for the Patent Rights) in each country in the Territory including without limitation the
registrations and pending applications for the Trademark and Patent Rights in each country listed in Appendix B as shall be reasonably useful or necessary to protect Celltech’s rights under this Agreement; provided,
however, that if Orphan Medical shall fail to file a useful or necessary application or maintain a useful or necessary registration for any trademarks, alternative trademarks or patents in a country in the Territory, or to maintain the
Trademark and Patent Rights registrations in each country listed in Appendix B, Celltech shall have the right to file such applications and maintain such registrations in each such country in the Territory for such trademarks, alternative
trademarks or patents at the expense and in the name and on behalf of Orphan Medical (or in Celltech’s own name if that is not permitted in the applicable country). Such registration and use of the Trademark and Patent Rights shall inure to the
benefit of and be on behalf of Orphan Medical. On any termination of this Agreement pursuant to Article XIV hereof, Celltech shall promptly assign to Orphan Medical registrations and any applications for registration of trademarks, alternative
trademarks or patents for the Product in the Territory filed in its name pursuant to this Section 10.4. 
  
 10.5 Reservation of Rights. Except as otherwise provided herein, (i) nothing in this Agreement shall entitle Celltech to any right, title or
interest in or to any of the Patent Rights, Know How, Manufacturing Know How, Trademark, Improvements, and Proprietary Information of Orphan Medical or any associated goodwill, which is and shall remain the sole and exclusive property of Orphan
Medical and (ii) Celltech shall not take and shall cause its Subdistributors, Sublicensees and Third Party manufacturers to not take any action that might (a) impair any right, title or interest of Orphan Medical in and to the Patent Rights, Know
How, Manufacturing Know How, Trademark, Improvements and Proprietary Information; or (b) create any right, title or interest in or to such Patent Rights, Know How, Trademark, Improvements and Proprietary Information in Celltech or any other Person.
Celltech acknowledges Orphan Medical’s proprietary rights as provided in the preceding sentence, and hereby waives in favor of Orphan Medical any right Celltech may have in and to the Patent Rights, Know How, Manufacturing Know How, Trademark,
Improvements and Proprietary Information except as herein provided. 
  
 ARTICLE XI 
 INTELLECTUAL PROPERTY INFRINGEMENTS 
  
 11.1 Protection of Intellectual Property. Celltech shall cooperate with Orphan Medical and take all reasonable
actions which Orphan Medical may reasonably request, at Orphan Medical’s sole cost and expense, in order to protect and enforce Orphan Medical’s intellectual property rights, including, but not limited to, carrying out any act Orphan
Medical may reasonably require in connection with any registration, enforcement or protection thereof. Celltech shall promptly notify Orphan Medical upon becoming aware of any use in the Territory by a Third Party of the Patent Rights, Know How,
Manufacturing Know How, Trademark, Improvements or Proprietary Information of Orphan Medical related thereto, or any other Orphan Medical intellectual property relating to the Product which may constitute an infringement thereof. Orphan Medical
shall have the first right, at its option, to institute proceedings against Third Party infringers in respect of infringements occurring in the Territory. If Orphan Medical elects not to institute such proceedings within a period of thirty (30) days
after its discovery of the infringement, Celltech shall have the right at its option to do so. The party instituting proceedings in the Territory pursuant to this Article XI shall bring all such 
  

 36 

 proceedings in the name of both parties. Orphan Medical shall have the exclusive right in its sole discretion to
institute proceedings solely in its name against Third Party infringers in respect of infringements occurring outside the Territory. Each party shall cooperate fully with the other party in connection with any such proceedings against third-party
infringers. All expenses of any such proceedings shall be borne by the party instituting the proceedings and damages which may be awarded or agreed upon in settlement of such action shall be allocated first to reimburse the documented costs of the
proceedings incurred by the party bringing suit, with the balance of such amounts, if any, to be allocated between the parties in accordance with their relative economic loss from such infringement. 
  
 ARTICLE XII 
 IMPROVEMENTS 
  
 12.1 Improvements by Celltech. Subject to Celltech’s rights therein as provided elsewhere in this Agreement, including without limitation Section 2.2, Celltech hereby irrevocably assigns, releases,
and transfers to Orphan Medical its entire right, title and interest in and to any Improvement solely relating to the API and/or Product (whether patentable or not) made or conceived solely by Celltech employees or contractors. 
  
 12.2 Improvements by Orphan Medical. Subject to Celltech’s rights
therein as provided elsewhere in this Agreement, including without limitation Section 2.2, Orphan Medical shall own all right, title and interest in and to any Improvement relating to the API and/or Product (whether patentable or not) made or
conceived solely by Orphan Medical employees or by any Orphan Medical contractor, other than Celltech, including, without limitation, any manufacturing or analytical process, procedure or method or any source of synthesis given to Celltech.

  
 12.3 Disclosure. Celltech shall promptly disclose to
Orphan Medical any and all Improvements relating to the API and/or Product by Celltech’s employees or contractors, either alone or together with Orphan Medical’s employees or contractors. Celltech shall execute at Orphan Medical’s
expense any assignments, applications or other instruments or documents reasonably requested by Orphan Medical to obtain, maintain, and otherwise to perfect Orphan Medical’s interest therein as provided by this Agreement. Celltech’s and
Orphan Medical’s obligations hereunder shall survive termination of this Agreement. 
  
 ARTICLE XIII 
 CONFIDENTIALITY 
  
 13.1 Proprietary Information. During the Term hereof and for a period of five (5) years thereafter, any Proprietary
Information disclosed by one party (the “Disclosing Party”), directly or indirectly, to the other party (the “Receiving Party”) under this Agreement shall be deemed confidential, and trade secret information,
whether so designated or not, and shall not be disclosed by the Receiving Party to any Third Party, except as set forth below. Access to such Proprietary Information shall be limited to employees, agents, consultants or contractors of the Receiving
Party who reasonably require such Proprietary Information for purposes of performing the Receiving Party’s obligations hereunder and who are bound to the Receiving Party by similar obligations in respect of confidentiality and use. Such
employees, agents, consultants or 
  

 37 

 contractors shall be advised of the nature and existence of the undertakings in respect of such Proprietary Information
pursuant to this Agreement and of the applicability of such undertakings to them. The Receiving Party shall use such Proprietary Information only to carry out its obligations or to exercise its rights hereunder and shall not use such Proprietary
Information for its own benefit or for the benefit of others or in any way inconsistent with this Agreement. 
  
 13.2 Exclusions. Information shall not be deemed Proprietary Information which: 
  
 (a) at the time of disclosure, is already in the public domain or thereafter becomes part of the public domain through no
act or omission of the Receiving Party; 
  
 (b) was rightfully in
the possession of the Receiving Party prior to the time of the disclosure; 
  
 (c) is independently disclosed to the Receiving Party by a Third Party who has not violated any confidential obligation owed to the Disclosing Party; 
  
 (d) was independently developed by the Receiving Party without any use of or reliance on any Proprietary Information of the
Disclosing Party; 
  
 (e) is required to be disclosed by legal
process, provided that, in each case the party so disclosing information timely informs the other and uses its best efforts to limit the disclosure and maintain confidentiality to the extent possible and permits the other party to attempt by
appropriate legal means to limit such disclosure; 
  
 (f) is
information which is required to be included in patent applications or required to be provided to the FDA or any other Regulatory Authority in the Territory in order that Registrations for the Product can be obtained or otherwise to comply with
applicable regulatory requirements; provided, however, that no Proprietary Information of Celltech or Orphan Medical shall be disclosed in any such patent application or Registration without the prior written consent of the Disclosing
Party, which consent shall not be unreasonably withheld; or 
  
 (g) is information which is required to be disclosed to customers, users, and prescribers of the Product or which is reasonably necessary to disclose in connection with the ethical marketing of the Product, if applicable. 
  
 13.3 Third Party Disclosure. Disclosure by the Receiving Party to a
Third Party shall be made only to the extent necessary to enable the Receiving Party to comply with its contractual obligations to the Disclosing Party, and only if such Third Party has executed a confidentiality agreement containing terms that are
at least as protective as the terms of this Agreement. 
  
 13.4
Third Party Confidentiality Agreement. Each Third Party to which Proprietary Information is disclosed other than a Regulatory Authority shall agree in writing prior to such disclosure to keep the Proprietary Information in strict confidence.

  

 38 

 13.5 Confidentiality of Agreement. Except as otherwise required by law, applicable regulations or
the terms of this Agreement or as mutually agreed upon by the parties hereto, each party shall treat as confidential the terms and conditions of this Agreement. 
  

13.6 Prior Confidentiality Agreement. The Confidentiality Disclosure Agreement between the parties hereto dated 20 November 2002 is hereby
superseded and terminated. Any disclosure of Proprietary Information by either party pursuant to such Confidentiality Agreement shall be deemed to have been made hereunder and shall be subject to this Article 13. 
  
 ARTICLE XIV 
 TERM AND TERMINATION 
  
 14.1 Term. This Agreement shall become effective as of the Effective Date and shall remain in full force and effect until the last of Orphan Medical’s Patent Rights to expire or ten (10) years from the
date Celltech receives approval from the EMEA to commercially promote and distribute the Product, whichever is longer. This Agreement will be automatically extended indefinitely thereafter unless and until terminated by Celltech upon not less than
twelve (12) months written notice to Orphan Medical. All references herein to “Term” or “Term of this Agreement” shall be deemed to include both the initial and any extended terms. 
  
 14.2 Mutual Termination. This Agreement may be terminated prior to its
normal Term as follows: 
  
 (a) Either party may terminate this
Agreement immediately upon notice if the other party files a petition of any type as to its bankruptcy, is declared bankrupt, becomes insolvent, makes an assignment for the benefit of creditors, goes into liquidation or receivership, or otherwise
loses legal control of its business involuntarily. 
  
 (b) Either
party may terminate this Agreement if the other party materially defaults or commits a material breach of this Agreement and has failed to cure such default or breach within ninety (90) days of receipt of written notice thereof from the first party.

  
 (c) Either party may terminate this Agreement in accordance
with Section 16.2 or Section 16.3. 
  
 14.3 Termination by
Orphan Medical. Orphan Medical may terminate this Agreement upon written notice to Celltech if any of the following continues uncured for a period of ninety (90) days following receipt of written notice thereof from Orphan Medical: 

 
 (a) Celltech shall have failed to meet the applicable minimum royalty
payment requirements for the Product as provided in Article IV hereof. 
  
 (b) Celltech ceases to sell the Product in the Territory. 
  
 (c) Celltech alters any Product except as permitted hereunder or with Orphan Medical’s prior written consent. 
  

 39 

 (d) Except as otherwise herein provided, as to the countries in which EMEA approval is required for a
Registration, if Celltech shall have failed to obtain a Registration in at least one Major European Country by December 31, 2006, and as to each other country in the Territory, if Celltech shall have failed to use Commercially Reasonable Efforts to
obtain a Registration in such country, if, in each case, such failure shall not be due to a breach by Orphan Medical of its obligations under this Agreement. 
  
 14.4 Rights and Obligations on Termination. In the event of termination of this Agreement for any reason, the parties shall have the following
rights and obligations: 
  
 (i) Neither party
shall be released from the obligation to make payment of all amounts then or thereafter due and payable in respect of the Term prior to such termination as otherwise herein provided. 
  
 (ii) Except as provided in Section 14.6, Celltech shall cease to market, promote, sell and distribute the
Product and shall return to Orphan Medical, at Celltech’s expense, all copies of promotional and technical materials and artwork provided by Orphan Medical; provided, however, that if this Agreement is terminated by Celltech
pursuant to Section 14.2(b), Orphan Medical shall pay all expenses related to such return of materials and artwork; 
  
 (iii) Orphan Medical may, if Celltech elects not to pursue its sell-off rights under Section 14.6, repurchase Celltech’s inventory of
non-obsolete and non-expired Product at the price paid by Celltech for such Product or direct Celltech to sell them to the Third Party or parties selected by Orphan Medical at the price paid by Celltech; provided, however, that if this
Agreement is terminated by Celltech pursuant to Section 14.2(b), Orphan Medical must repurchase such inventory at the price paid by Celltech if Celltech elects not to pursue its sell-off rights under Section 14.6; 
  
 (iv) Celltech shall return or, if requested by Orphan
Medical, destroy all of Orphan Medical’s Proprietary Information, including, if applicable, all electronic copies thereof and shall certify in writing that it has done so; and 
  
 (v) Celltech shall comply with the provisions of Section 10.4 regarding the assignment to Orphan Medical of
trademark and/or patent rights registrations filed in Celltech’s name. 
  
 14.5 Partial Termination. In the event that a cause of termination shall relate solely to any country not subject to regulation by the EMEA, then termination of this Agreement shall be limited and applied only
to such country or portion of the Territory. 
  
 14.6 Sell-Off
Period. Notwithstanding anything to the contrary in Section 14.4 hereto, upon expiration or termination of this Agreement, Celltech shall have the right to continue to distribute its existing inventory of non-expired Product for a period of six
(6) months after the effective date of expiration or the effective date of termination of this Agreement as the case may be. Any such continued distribution shall be in accordance with all applicable laws and regulations and the terms of this
Agreement. 
  

 40 

 14.7 Survival. The provisions of Articles I (Definitions), VIII (Representations &
Warranties), IX (Indemnification), XIII (Confidentiality), XIV (Term and Termination), XV (Arbitration), and XVII (Miscellaneous), as well as the provisions of Articles III (Compliance with Laws and Regulations), XI (Intellectual Property
Infringement), XII (Improvements) Article XIII (Confidentiality), Article XIV (Termination), Article XV (Arbitration), Article XVII (Miscellaneous) and the other provisions hereof which by their terms are intended to survive the expiration or
termination of this Agreement (including without limitation, Sections 3.4 (Return of Initial Payment), Section 4.8 (Books and Records) and Section 7.3(e) (Consignment of Product – Return of Consignment Inventory) shall survive any termination
or expiration of this Agreement. 
  
 14.8 Assignment of
Authorizations. As soon as possible following the expiration or earlier termination of this Agreement, Celltech shall take all necessary steps to ensure expeditious assignment of all Marketing Authorizations and Orphan Drug Designations which
are in Celltech’s name to Orphan Medical. If an assignment to Orphan Medical is prohibited under the laws of a country in the Territory, Celltech agrees to and hereby grants Orphan Medical authorization to distribute the Product under such
Marketing Authorization until Orphan Medical or its designee has obtained Marketing Authorizations and Orphan Drug Designations in its own name for the Product in that country; provided that Orphan Medical shall defend, indemnify and hold
harmless Celltech from and against all Claims and Indemnification Amounts of whatsoever kind or nature that result from, arise out of or relate to Orphan Medical’s distribution of the Product under the Marketing Authorizations and Drug
Designations continuing in Celltech’s name as contemplated by this Section 14.8. 
  
 14.9 Rights on Termination for Cause. In the event of termination of this Agreement by Orphan Medical pursuant to the provisions of Sections 14.2(a) or (b) or 14.3 (a) – (c), Celltech shall provide to
Orphan Medical, at no expense to Orphan Medical, its then current list of prospects and customers, including company name, contact, address and telephone number. 
  
 14.10 No Compensation. In the event of any expiration or termination of this Agreement for any reason, neither party
shall owe any compensation to the other party for lost profits, lost opportunities, good will, or any other loss or damage in respect of future periods as a result of or arising from such termination or expiration. 
  
 ARTICLE XV 
 ARBITRATION 
  
 15.1 Litigation Rights Reserved. If any dispute arises with respect to the unauthorized use of Proprietary Information by either Party or, Orphan Medical’s Trademark, Patent Rights, Know How, Manufacturing Know How, and
Improvements by Celltech, or with respect to acts or omissions of Celltech or Orphan Medical relating to the Product which in the good faith discretion of Orphan Medical or Celltech, as the case may be, negatively impact the safety of the public,
Orphan Medical or Celltech, as the case may be, may seek any available equitable remedy from a court of competent jurisdiction. 
  
 15.2 Arbitration. Except as provided in Sections 7.13 and 15.1, all disputes arising between the parties in connection with this Agreement shall be
settled through friendly 
  

 41 

 consultations between the parties and if no agreement can be reached through consultations, they shall be submitted to
arbitration for settlement. The arbitration shall take place in New York, New York, and be conducted by the American Arbitration Association in accordance with the commercial arbitration rules thereof (the “Rules”) except as
modified hereby. All necessary determinations, including the arbitration decision, shall be made by a panel of three arbitrators (the “Panel”). Within ten (10) days after delivery of a notice of arbitration, each of the two parties
shall select one arbitrator as a member of the Panel. The two parties shall select as the third member of the Panel an independent arbitrator with no past or current business affiliations with either party, and if the parties cannot agree on such
independent arbitrator within ten (10) days after delivery of a notice of arbitration, such independent arbitrator shall be selected in accordance with the Rules. The Panel shall establish a schedule of discovery and hearing such that the
Panel’s final written decision shall be issued within one hundred and twenty (120) days after selection of the independent arbitrator serving on the Panel. Each party must produce all relevant non-privileged documents requested by the other
party within thirty (30) days after the request therefor. The Panel’s decision must be in writing and shall set forth the reasons therefor. Such decision shall be conclusive determination of the matter and binding on the parties, shall have the
effect of an arbitration award, and shall not (to the extent permitted by applicable law) be contested by any of them. The fees and expenses of an arbitrator selected by a party shall be borne by such party. The fees and expenses of the third
independent arbitrator shall initially be borne equally by the parties, and shall be allocated between the parties in accordance with the final decision of the Panel, which decision shall allocate such fees between the parties as determined by the
Panel. 
  
 15.3 Governing Law. This Agreement shall be
governed by, and interpreted and construed in accordance with, the laws of the State of New York, U.S.A., excluding (i) its choice of law rules and (ii) the United Nations Convention on the International Sale of Goods, provided that
(x) enforcement and operation of the Consignment Inventory arrangements in Section 7.3 shall be governed by the laws of England, and (y) enforcement and operation of the arbitration agreement contained in Section 15.2 hereof, and the enforcement of
any award rendered pursuant thereto, shall be governed by United States federal law to the exclusion of State law. 
  
 ARTICLE XVI 
 FORCE MAJEURE 
  
 16.1 Events of Force Majeure. Anything in this Agreement to the
contrary notwithstanding, neither party shall be liable or responsible for any failure or delay in performance (excluding payment of sums owed hereunder) due to causes affecting such party and, in the case of Orphan Medical, its designated
suppliers, and, in the case of Celltech, its Subdistributors, Sublicensees and Third Party manufacturers, beyond the reasonable control of such party, including, without limitation, any act of God; regulation or law of any government or an agency
thereof, excluding, however, if a Regulatory Authority enjoins manufacture of the Product or otherwise closes the Product manufacturing facilities due to Orphan Medical’s failure to comply with cGMP or any other breach by Orphan
Medical of its obligations under this Agreement; war; terrorism; insurrection or civil commotion; earthquake, tornado, fire, flood or storm; epidemic; or failure of public utilities or common carriers. Such excuse shall continue as long as the
condition preventing the performance continues. Upon cessation of such condition, such party shall promptly resume performance hereunder. 
  

 42 

 16.2 Notice. A party affected by an event of force majeure shall give the other party prompt
written notice of the occurrence of any event of force majeure and the nature and duration thereof. An affected party shall use all Commercially Reasonable Efforts to resume performance as quickly as possible and to give the other party prompt
written notice when it is again fully able to perform such obligations. If such event of force majeure continues for more than one hundred eighty (180) days, either party may terminate this Agreement by giving ten (10) days written notice to the
other party. If Celltech is the affected party, such notice of resumption of performance shall state the quantities of Product Orphan Medical needs to ship to enable Celltech to resume performance of obligations. 
  
 16.3 Hardship. In the event that, during the Term, any law or
government-enacted regulation or decree renders the performance by either party of its respective obligations hereunder unduly onerous or infeasible to implement, Celltech and Orphan Medical shall consult each other and show mutual understanding
with a view to making such adjustments as would appear to be necessary and feasible. The party who considers that the change in regulation or decree is unduly onerous or infeasible to implement, shall notify the other within ninety (90) days of the
change in regulation or decree, specifying the specific date and change, an evaluation of the hardship which is or shall be suffered and the proposal made by it to remedy that change if feasible. If the parties fail to reach an agreement within
ninety (90) days after the date of the notice, either party shall at any time thereafter be entitled to terminate this Agreement upon written notice only with respect to the country or countries affected by such change in regulation or decree.
 
  
 ARTICLE XVII 
 MISCELLANEOUS 
  
 17.1 Notices. All notices to the parties shall be made at the following addresses (or at such other address as shall be specified by it by like
notice): 
  

			
	 To:
	  	Orphan Medical, Inc.
	 	  	Attention: Chief Executive Officer
	 	  	13911 Ridgedale Drive, Suite 250
	 	  	Minnetonka, Minnesota 55305
	 	  	United States
	 	  	Copy: Director of International Business
	 	  	Fax: 952 540 9209

  

			
	 To:
	  	 Celltech Pharmaceuticals Ltd.

	 	  	 Attention: Chief Executive Officer

	 	  	 208 Bath Road

	 	  	 Slough, Berkshire SL1 3WE

	 	  	 United Kingdom

	 	  	 Copy: Company Secretary

	 	  	 Fax: 011 44 175 353 6632

  
 Notices permitted or
required to be given hereunder shall be deemed sufficient if given by (a) registered or certified airmail, postage prepaid, return receipt requested, (b) private 
  

 43 

 courier service or (c) facsimile transmission with electronic confirmation of receipt. Notices so given shall be
effective (1) upon receipt by the party to whom notice is given, or (2) on the tenth (10th) day following international mailing, as may be the case, whichever occurs first. 
  
 17.2 Waiver. No failure by either party to take any action or assert any right hereunder shall be deemed to be a
waiver of such right in the event of the continuation or repetition of the circumstances giving rise to such right. 
  
 17.3 Entire Agreement. This Agreement and the Schedules and Appendices hereto constitute the entire agreement of the parties with respect to the
subject matter hereof, and supersede all previous agreements by and between the parties as well as all proposals, oral or written, and all negotiations, conversations or discussions heretofore had between the parties related to this Agreement.

  
 17.4 Amendment. No modification or amendment of this
Agreement shall be binding unless in writing and signed by both parties. 
  
 17.5 Headings. Article, section and paragraph headings used in this Agreement are for convenience only, have no legal significance, and in no way change the construction or meanings of the terms hereof.

  
 17.6 Relationship of the Parties. The parties shall be
deemed independent contractors of each other and, as such, they shall not be entitled to any benefits applicable to employees of the other party. Nothing contained in this Agreement shall be construed or implied to create an agency, partnership, or
employer and employee relationship between Orphan Medical and Celltech. At no time shall one party make commitments or incur any charges or expenses for or in the name of the other party except as specifically provided herein. 
  
 17.7 Assignment. Neither party may assign this Agreement without the
prior written consent of the other party except that either Orphan Medical or Celltech may assign this Agreement (a) to an Affiliate or (b) in connection with a merger, stock sale, or the sale or transfer of all or substantially all of the assets of
such party or the division of such party manufacturing or marketing the Product, as the case may be, provided, however, any permitted assignee shall assume all obligations of its assignor under this Agreement and in the case of clause (a), the
assigning party shall remain primarily liable for the performance of such Affiliate. Any purported assignment in violation of the foregoing sentence shall be null and void. No assignment shall relieve either party of responsibility for the
performance of any accrued obligation under this Agreement. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the permitted successors or permitted assigns of Celltech and Orphan Medical, respectively.

  
 17.8 Severability. If any term or condition of this
Agreement is found by a court of competent jurisdiction to violate the provisions of any applicable statute, law or regulation, the remainder of this Agreement shall remain in full force and effect. The parties shall then negotiate in good faith to
modify this Agreement, to the extent necessary to make the affected term or condition of this Agreement valid and enforceable, having full regard for the original intent of the parties. 
  

 44 

 17.9 Publicity. This Agreement is confidential and neither party shall issue press releases or
engage in other types of publicity of any nature (whether written or oral) dealing with the existence or details of this Agreement without the other party’s prior written approval, which approval shall not be unreasonably withheld;
provided that, approval of such disclosure shall be deemed to be given to the extent such disclosure is required to comply with governmental rules, regulations or requirements. In such event, the disclosing party shall furnish a copy
of such disclosure to the other party. 
  
 17.10
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same Agreement. This Agreement may be executed and delivered via
facsimile transmission with the same force and effect as if it were executed and delivered in writing. In making proof of this Agreement, it shall not be necessary to produce or account for more than one fully executed counterpart. 
  
 17.11 LIMITATION OF DAMAGES. NEITHER ORPHAN MEDICAL NOR CELLTECH SHALL
HAVE ANY LIABILITY OF ANY KIND TO THE OTHER PARTY FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL LOSSES OR DAMAGES, EVEN IF ORPHAN MEDICAL OR CELLTECH, AS THE CASE MAY BE, SHALL HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH POTENTIAL LOSS OR
DAMAGE BY THE OTHER PARTY. FOR PURPOSES OF THE LIMITATION OF LIABILITY IN THE IMMEDIATELY PRECEDING SENTENCE, (i) LEGAL FEES AND EXPENSES THAT ARE RECOVERABLE AS PROVIDED IN ARTICLE IX SHALL NOT BE CONSIDERED INDIRECT DAMAGES, (ii) INDIRECT DAMAGES
PAYABLE BY AN INDEMNIFIED PARTY TO A THIRD PARTY THAT WOULD BE RECOVERABLE UNDER THE INDEMNITY PROVISIONS IN ARTICLE IX BUT FOR SUCH LIMITATION OF LIABILITY SHALL BE RECOVERABLE NOTWITHSTANDING SAID LIMITATION OF LIABILITY AND (III) LOST PROFITS
SHALL NOT BE DEEMED TO BE SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES EXCEPT IN RESPECT OF FUTURE PERIODS FOLLOWING A TERMINATION OF THIS AGREEMENT IN ACCORDANCE WITH THE TERMS HEREOF. 
  

 45 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement by their respective duly
authorized representatives as of the Effective Date. 
  

			
	 CELLTECH PHARMACEUTICALS LTD.

		
	 By:
	 	  
 /s/    Goran Ando        

	 	 	 Name: Goran Ando

	 	 	 Title: CEO

  

			
	 ORPHAN MEDICAL, INC.

		
	 By:
	 	  
 /s/    John H. Bullion        

	 	 	 Name: John H. Bullion

	 	 	 Title: CEO

 APPENDIX A  
  
 TERRITORY 
  

			
	 Major European Countries
	  	Minor European Countries
		
	 France
	  	Austria
	 Germany
	  	Belgium
	 Italy
	  	Czech Republic
	 Spain
	  	Denmark
	 United Kingdom of Great Britain and Northern Ireland
	  	Estonia
	 	  	Finland
	 	  	Greece
	 	  	Hungary
	 	  	Iceland
	 	  	Ireland
	 	  	Latvia
	 	  	Lithuania
	 	  	Luxemburg
	 	  	Malta
	 	  	Netherlands
	 	  	Norway
	 	  	Poland
	 	  	Portugal
	 	  	Slovak Republic
	 	  	Slovenia
	 	  	Sweden
	 	  	Switzerland
	 Option Countries
	  	 
		
	 Turkey
	  	 

  

 A-1 

 APPENDIX B  
  
 TRADEMARK 
  
  

			
	 Xyrem®
	  	 
	 European Community Trademark
	  	 Reg. No.: 957712
 Registered: 10 March 2000

	 Norway
	  	 Reg. No.: 217395
 Registered: 23 January 2003

	 Iceland
	  	 Reg. No.: 679/2002
 Registered: 31 July 2002

	 Switzerland
	  	 Reg. No.: 503.859
 Registered: 9 October 2002

	 Czech Republic
	  	 Reg. No.: 251135
 Registered: 27 January 2003

	 Slovak Republic
	  	 Application No.: POZ 1676-2002
 Registered: Pending

	 Poland
	  	 Appl. No.: Z-251131
 Registered: Pending

	 Hungary
	  	 Appl. No.: M 02 02667
 Registered: Pending

  
 PATENT RIGHTS

  

											
	 Country

	  	Stage

	  	Serial #

	  	Date Filed

	  	Patent #

	  	Issue Date

	 European
	  	Granted	  	99964320.8	  	12/22/99	  	1140061	  	5/2/03
	 Austria
	  	Granted	  	99964320.8	  	12/22/99	  	1140061	  	5/2/03
	 Belguim
	  	Granted	  	99964320.8	  	12/22/99	  	1140061	  	5/2/03
	 Denmark
	  	Granted	  	99964320.8	  	12/22/99	  	1140061	  	5/2/03
	 Finland
	  	Granted	  	99964320.8	  	12/22/99	  	1140061	  	5/2/03
	 France
	  	Granted	  	99964320.8	  	12/22/99	  	1140061	  	5/2/03
	 Germany
	  	Granted	  	99964320.8	  	12/22/99	  	69907508.408	  	5/2/03
	 Ireland
	  	Granted	  	99964320.8	  	12/22/99	  	1140061	  	5/2/03
	 Italy
	  	Granted	  	99964320.8	  	12/22/99	  	1140061	  	5/2/03
	 Netherlands
	  	Granted	  	99964320.8	  	12/22/99	  	1140061	  	5/2/03
	 Spain
	  	Granted	  	99964320.8	  	12/22/99	  	1140061	  	5/2/03
	 Sweden
	  	Granted	  	99964320.8	  	12/22/99	  	1140061	  	5/2/03
	 Switzerland
	  	Granted	  	99964320.8	  	12/22/99	  	1140061	  	5/2/03
	 United Kingdom
	  	Granted	  	99964320.8	  	12/22/99	  	1140061	  	5/2/03

  

 B-1 

 APPENDIX C 
  

PRODUCT SPECIFICATIONS 
  

			
	 Xyrem® (sodium oxybate) oral solution

	 Expiration Period:
	 	 48 months

	 Storage Conditions:
	 	 15 - 30°C

	 Release Specifications:
	 	 

  
                                     * 
  
 Approval Signatures on File: 
  
 Regulatory Affairs 
  
 Verified By:
                                        

  

 C-1 

 APPENDIX D 
  

STANDARD OPERATING PROCEDURE FOR EXCHANGE OF SAFETY DATA 
  
 The Orphan Medical and Celltech individuals in charge of pharmacovigilance shall follow the procedure outlined below in
reporting adverse experiences. 
  
 1. Definitions.
Definitions shall be those in use by the International Conference on Harmonization (ICH) as may be amended by ICH from time to time. Current definitions are: 
  
 1.1. Adverse Event (“AE”) means any untoward medical occurrence in a patient or clinical investigation subject administered a
pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily
associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. 
  
 1.2. Serious Adverse Event (“SAE”) means any untoward medical occurrence that at any dose: 
  

	 	•	results in death, 

  

	 	•	is life-threatening, 

  

	 	•	requires inpatient hospitalization or prolongation of existing hospitalization, 

  

	 	•	results in persistent or significant disability/incapacity, or 

  

	 	•	results in a congenital anomaly/birth defect. 

  
 1.3. Adverse Drug Reaction (“ADR”) 
  

	 	•	ADRs in the clinical setting refer to all noxious and unintended responses to a medicinal product (i.e., where the relationship between an adverse event and product can not be ruled
out) related to any doses. 

  

	 	•	ADRs regarding marketed medicinal products shall refer to a response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis,
diagnosis, or therapy of disease or for modification of physiological function. 

  
 1.4. Serious Adverse Drug Reaction (“SADR”) means an ADR having the characteristics described in 1.2. 
  
 1.5. Unexpected Adverse Drug Reaction (“UADR”) means an ADR, the nature or severity of which is not consistent with the applicable
product information (e.g., Investigator’s Brochure for an unapproved investigational product or package insert for an approved product.) 
  

 D-1 

 2. Transmission of data between Orphan Medical and Celltech. 
  
 2.1. In the context of clinical trials: 
  
 2.1.1. All the SAEs related (expected and unexpected) to the drug as
assessed by investigators shall be forwarded on a quarterly basis under the form of tabulated summary in English. Such summary shall bear at least the following information: patient’s ID number, protocol identification, Investigator Center,
type of serious event, symptomatology or pathology observed, notified SAE. These clinical or biological manifestations shall be named according to the dictionary in use by each party (e.g. MeDRA or WHO). 
  
 2.1.2. Each party, upon request, may receive available additional or
follow-up data from the other party. 
  
 2.2. In the context of
post-marketing surveillance: 
  
 2.2.1. In the case of SAEs, the
parties shall exchange data within five (5) days of becoming aware of such SAE. In the case of SADRs and UADRs, the parties shall exchange data within ten (10) days after becoming aware of such SADR or UADR. In the case of any other AE or ADR the
parties shall exchange data within thirty (30) days of becoming aware of such AE or ADR. 
  
 2.3. All information between the parties shall be sent using the standard reporting format for Health Authorities in force in the respective countries concerned. 
  

 D-2 

 APPENDIX E 
  

QUALITY AGREEMENT 
  
 * 
  

 E-1 

 APPENDIX F 
  

CELLTECH FIRST COMMERCIAL YEAR FORECAST 
  
 * 
  

 G-1 

 APPENDIX G 
  

COMPONENTS OF STANDARD MANUFACTURING COST 
 AND 
 TRANSFER PRICE 
  
 * 
  

 G-2 

 APPENDIX H 
  

REGULATORY ASSISTANCE 
  
 1. Marketing Authorizations and Registrations 
  
 In connection with Celltech’s acquisition of the Marketing Authorizations and Registrations and in addition to Orphan Medical’s obligations set
forth elsewhere in this Agreement, Orphan Medical will, at its own cost and expense (but subject to the limitations set forth in Section 3.2), take the following actions: 
  

	 	A.	Promptly provide Celltech with copies of the NDA(s) and other relevant Know How and documentation currently in Orphan Medical’s possession; 

  

	 	B.	On Celltech’s reasonable request, provide reasonable assistance in reviewing Product clinical studies; and 

  

	 	C.	Promptly review and comment upon, as necessary, all applications for Marketing Authorizations and supporting documentation that Celltech shall submit to Orphan Medical for review
prior to filing with the appropriate Regulatory Authorities in the Territory. 

  
 2. Training, Sales and Technical Literature. 
  
 In addition to the materials that Orphan Medical is to provide Celltech pursuant to Section 6.5 of this Agreement, Orphan Medical shall also provide to Celltech in accordance with Section 6.5, the following materials:

  

	 	A.	All training materials used by Orphan Medical during the Term; 

  

	 	B.	Copies of all studies relating to the Product conducted by or on behalf of Orphan Medical, and all updates thereto; 

  

	 	C.	During each of the first three (3) years of the Term, Orphan Medical, at its sole cost and expense, shall provide five (5) eight (8) hour days of sales and technical training to
Celltech’s employees, agents, independent contractors, Subdistributors or Sublicensees at the Celltech facility specified by Celltech. Celltech and Orphan Medical shall use Commercially Reasonable Efforts to coordinate mutually convenient days
for such training; provided, however, if the parties cannot agree on a mutually convenient time for Orphan Medical to provide such services, Celltech shall designate the dates for such training and notify Orphan Medical thereof at
least thirty (30) days prior to the first designated training date. 

  

 H-1 

 APPENDIX I 
  

TRADEMARK USE STANDARDS 
  
 * 
  

 I-1Amendment to Option Agreement and Agreement dated as of  04/15/2004

 * CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. REDACTED
PORTIONS OF THIS EXHIBIT ARE MARKED BY AN *. 
  
 Exhibit 4.26

  
 Execution Copy 
 CONFIDENTIAL 
  
 AMENDMENT TO OPTION AGREEMENT AND AGREEMENT 
  
 This Amendment (this “Amendment”) to Option Agreement, dated July 23, 2002, between the parties hereto (the “Option
Agreement”) and the Agreement, dated July 23, 2002, between the parties hereto (the “License Agreement”) is made as of April 15, 2004 (the “Date of this Amendment”) by and between Pfizer Health AB (formerly
Pharmacia AB), a corporation organized and existing under the laws of Sweden (“Pfizer”), and Celltech Pharmaceuticals Ltd., a corporation organized and existing under the laws of England (“Celltech”). 
  
 WHEREAS, Celltech and Pfizer desire to amend certain terms and conditions of
the Option Agreement and the License Agreement to effect early exercise of Celltech’s Purchase Option as set forth herein. 
  
 NOW THEREFORE, in consideration of the premises and of the mutual covenants and obligations set forth herein, the parties hereto agree as set out below.

  
 1. Definitions. For purposes of this
Amendment, all capitalized terms which are used but not defined in this Amendment will have the meanings ascribed to them in the Option Agreement or the License Agreement, as the case may be. 
  
 2. Purchase Option. (a) The parties desire to
accelerate the completion of the Purchase Option from January 2005 as set forth in Section 2.1 of the Option Agreement to the Date of this Amendment. Therefore, the definition of Purchase Option Closing Date contained in Article I of the Option
Agreement is hereby amended so that the Purchase Option Closing Date shall be the Date of this Amendment. For clarity, all references to the Purchase Option Closing Date in the Option Agreement, including without limitation such references in
Sections 2.4 (Sale of Remaining Interest) and 3.1 (Royalties owed by Celltech), shall mean the Date of this Amendment; provided, however, the time within which the Remaining Interest Closing Date must occur, as provided by Section 2.4 of the Option
Agreement shall be amended to be during the period between six (G) months and twelve (12) months after the Purchase Option Closing Date. 
  
 (b) Section 2.7 of the Option Agreement is amended as necessary to reflect the parties’ agreement that they shall use their
commercially reasonable efforts to effectuate the transfer of the Product and the Product Proprietary Rights in the Territory within sixty (60) days following the Purchase Option Closing Date and otherwise in accordance with Section 2.7 of the
Option Agreement. Without limiting the terms of the Option Agreement, including those terms in Section 2.7 and Exhibit B of the Option Agreement, as soon as practicable after the Purchase Option Closing Date Pfizer shall deliver to Celltech an
archived copy of the NDA, confirmation of satisfactory completion of all post-approval commitments, and a copy of the IND, Pfizer shall permit Celltech to engage in discussions with the FDA and * with 

 respect to all regulatory aspects relevant to the manufacture and sale of the Product in the Territory
and Pfizer shall cooperate with Celltech to the full extent contemplated by Exhibit B to the Option Agreement. 
  
 3. Exercise Price. Section 2.2(a)(i) of the Option Agreement is hereby amended so that the amount due and payable *. For clarity,
Sections 2.2(a)(ii) and 2.2(b) of the Option Agreement are not affected by this Amendment. 
  
 4. Remaining Interest Purchase. (a) Within six (6) months following the Purchase Option Closing Date, Celltech shall pay to Pfizer
*. Such payment shall be credited against the Remaining Interest Purchase Price to be calculated in accordance with Section 2.5 of the Option Agreement; provided, however, that (i) Section 2.5 is amended to provide that the Remaining Interest
Purchase Price shall be * and shall be payable in respect of each country within ten (10) calendar days of the date on which the Product and Product Proprietary Rights are transferred to Celltech for such country (each date being a “Country
Closing Date”); (ii) in the event that (A) a Governmental Authority provides a final determination that the Product and the Product Proprietary Rights may not be transferred to Celltech or Pfizer shall have breached its obligations under
Section 4(b) hereof as of the date that is twelve (12) months after the Purchase Option Closing Date and (B) the aggregate amount payable pursuant to clause (i) as of such date shall be * and (iii) for this purpose Inventory shall mean any and all
Product in finished package form in Pfizer’s or its Affiliates’ possession in each country Throughout the World on the Country Closing Date for such country with a Labeled expiration date that is more than eighteen (18) months after such
Country Closing Date. 
  
 (b) During the period
between six (6) months following the Purchase Option Closing Date and twelve (12) months following the Purchase Option Closing Date, the parties shall use their commercially reasonable efforts to effectuate the transfer of the Product and Product
Proprietary Rights Throughout the World in accordance with Section 2.7 of the Option Agreement. For clarity, “commercially reasonable efforts” as used in this Section 4(b) as to Pfizer includes, without limitation, providing to Celltech
those documents with respect to each jurisdiction Throughout the World that are similar to the documents enumerated in Section 2(b) hereof plus information concerning pricing and pack sizes, and the transitional services set forth on Exhibit B to
the Option Agreement in accordance with the terms thereof. Except with respect to * in the event the transfer of the Product and Product Proprietary Rights in any country Throughout the World is not completed by twelve (12) months following the
Purchase Option Closing Date despite Pfizer’s commercially reasonable efforts to do so, then Pfizer shall have the right to withdraw the Product in such country in its sole discretion by providing Celltech at least a sixty (60) day written
notice. That is, for example, if Pfizer intends to withdraw the Product in a country Throughout the World * at twelve (12) months following the Purchase Option Closing Date, Pfizer must provide such written notice to Celltech no later than ten (10)
months following the Purchase Option Closing Date. 
  
 5. Section 2.8 of the Option Agreement is amended to provide that Pfizer also grants to Celltech a limited license (i) to sell after the Purchase Option Closing Date all Inventory Labeled with the name “Pharmacia” and (ii) to
deplete the inventory of packaging materials supplied pursuant to Section 8 below by packaging and selling Product Labeled with 
  

 2 

 the name “Pharmacia” after the Purchase Option Closing Date; provided, however, such limited
license shall expire (i) with respect to Inventory and packaging materials relating to the Territory, * after the date on which the Product and Product Proprietary Rights are transferred in the Territory, and (ii) * after each Country Closing Date
with respect to Inventory and packaging materials relating to the applicable country Throughout the World. 
  
 6. Regulatory Obligations. Until such time as the exercise of the Purchase Option and the Remaining Interest shall have been closed
and the transfer of the Product and Product Proprietary Rights in the Territory and Throughout the World shall have been effectuated in accordance with Section 2.7 of the Option Agreement and this Amendment, Pfizer’s regulatory obligations
under the Option Agreement and the License Agreement shall be to continue to provide (a) in each country until such sale has been consummated in respect thereof, (i) the same regulatory services and functions as are currently being provided plus,
(ii) if not provided pursuant to clause (i), such other regulatory services and functions as are provided in the License Agreement and this Amendment or are necessary to comply with the laws applicable in such country, including without limitation
PSURs, application renewals, responses to regular inquiries on pending or approved indications and safety reporting, and (b) any and all regulatory support required by the Regulatory Plan, as periodically updated in accordance with the terms of the
Option Agreement. For clarity, Pfizer shall not be required to provide regulatory support relating to filings or variations for line or indication extensions or any lifecycle enhancement initiatives. 
  
 7. Supply Obligations. (a) Sections 5.4 (a) and (b)
of the Option Agreement are amended and restated in their entirety as follows: 
  
 “5.4 Continued Manufacture by Pfizer. Pfizer shall continue to supply Celltech with Celltech’s requirements for Product not fulfilled from Celltech’s own production facilities until * (the
“Supply Term”) in accordance with the terms of Article IV of the License Agreement; provided, however, commencing as of * until expiration of the Supply Term (the “Remaining Supply Term”), Sections 4.3(d) and 4.4
thereof shall not be effective and the purchase price for Product (exclusive of Inventory acquired pursuant to Sections 2.2 and 2.4 of the Option Agreement) purchased by Celltech for sale in the Territory or Throughout the World shall be * (the
“Supply Price”). The parties acknowledge and agree that *. For the Remaining Supply Term, Pfizer shall *. At the end of the Remaining Supply Term, Pfizer may adjust the Supply Price, if necessary, *. Such adjustment will be * in the
Remaining Supply Term as compared to *. The parties shall make payment of such adjustment amount within ten (10) calendar days of Pfizer’s determination. For clarity, Pfizer shall have no obligation to manufacture or supply the Product after
the Supply Term. The parties shall cooperate and use their commercially reasonable efforts to transfer the manufacture of the Product to a 
  

 3 

 Celltech-designated facility prior to the expiration of the Supply Term.” 
  
 (b) Section 8.1 of the License Agreement is hereby amended and restated in
its entirety as follows: 
  
 “8.1 Term. The term of
this Agreement (the “Term”) shall commence on the Effective Date and unless earlier terminated in accordance with this Agreement shall continue until January 31, 2006. The purchase price of the Product for sale in the Territory delivered
from January 1, 2005 to January 31, 2006 shall be as set forth in Section 5.4 of the Option Agreement, as amended by the Amendment.” 
  
 (c) Section 4.2 of the License Agreement is hereby amended and restated in its entirety as follows: 
  
 “4.2 Celltech Product Projections. Celltech shall provide Pfizer
with * rolling projections of anticipated requirements of Product by SKU, including Product sample requirements, to assist Pfizer to adequately anticipate and meet Celltech’s requirements for the Territory and Throughout the World. Celltech
shall provide such forecast on the first business day of each calendar month. The projections shall be based on Celltech’s reasonable business judgment; provided that (i) Celltech shall always be obligated to purchase the amount forecast * in
each forecast and (ii) prior to the Remaining Supply Term, Celltech shall be obligated to purchase the Minimum Required Purchase Amount as provided in Section 4.3(d).” 
  
 8. Remaining Inventory. At the expiration of the Supply Term, Celltech shall purchase from Pfizer,
and Pfizer shall sell to Celltech, its inventory of materials used solely in the manufacture and packaging of the Product, including without limitation, the active pharmaceutical ingredient of the Product and packaging materials, at Pfizer’s
cost; provided, however, except as set forth below, such materials shall be usable in the ordinary course of manufacturing and packaging the Product and, if applicable, have a shelf life of eighteen (18) months or more. Notwithstanding the
foregoing, Celltech’s obligation to purchase materials under this Section shall apply even to packaging materials which become obsolete due to Celltech’s actions after the Date of this Amendment (such as Celltech’s decision to change
the artwork of packaging materials or Celltech’s failure to order the forecasted quantities). Celltech shall also assume any obligation to purchase active pharmaceutical’ ingredient of the Product under the * Supply Agreement outstanding
at the expiration of the Supply Term. Celltech’s obligation to purchase materials under this Section shall be limited to the extent the quantities of the remaining materials are generally consistent with the forecasts submitted by Celltech or
other written requests of Celltech. 
  

 4 

 9. Representations and Warranties. Section 4.2 of the Option Agreement is amended
to change the reference date “December 31, 2004” to be “ March 31, 2004.” 
  
 10. Confidential Information. For the purposes of Section 7.1 of the Option Agreement, as to the Territory from and after the
Purchase Option Closing Date and as to each country Throughout the World from and after the Country Closing Date for such country, Confidential Information of Pfizer with respect to the Product and the Product Proprietary Rights shall be deemed to
be Confidential Information of Celltech and Pfizer shall be deemed to be the recipient thereof from Celltech. 
  
 11. Entire Agreement. This Amendment together with the Option Agreement and the License Agreement constitute the entire
understanding and agreement between the parties hereto and supersede all previous writings and understandings between the parties hereto with respect to the subject matter hereof. No term or provision of this Amendment shall be varied or modified by
any prior or subsequent statement, conduct or act of either of the parties hereto, except that the parties hereto may amend this Amendment by written instruments specifically referring to and executed in the same manner as this Amendment. In the
event any of the provisions in this Amendment shall be inconsistent with the provisions of the Option Agreement or the License Agreement, as the case may be, the provisions in this Amendment shall govern. 
  

 5 

 IN WITNESS WHEREOF, the parties hereto have caused their authorized representatives to execute this
Amendment as of the date first above written. 
  

			
	 CELLTECH PHARMACEUTICALS LTD.

		
	By:	 	 /s/    Peter V. Allen        

	 	 	

	 	 	Name: Peter V. Allen
	 	 	Title:   CFO

			
	
	PFIZER HEALTH AB
		
	By:	 	 /s/    Thomas Backlund        

	 	 	

	 	 	Name: Thomas Backlund
	 	 	Title:

			
		
	By:	 	 /s/    Ulf Arnesson        

	 	 	

	 	 	Name: Ulf Arnesson
	 	 	Title:

  

 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}]]